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SUMMARY		29	
GDF15	is	an	established	biomarker	of	cellular	stress.	The	fact	that	 it	signals	via	a	specific	hindbrain	30	
receptor,	GFRAL,	and	that	mice	lacking	GDF15	manifest	diet-induced	obesity,	suggest	that	GDF15	may	31	
play	a	physiological	role	in	energy	balance.	We	performed	experiments	in	humans,	mice	and	cells	to	32	
determine	 if	and	how	nutritional	perturbations	modify	GDF15	expression.	Circulating	GDF15	 levels	33	
manifest	very	modest	changes	in	response	to	moderate	caloric	surpluses	or	deficits	in	mice	or	humans,	34	
differentiating	 it	 from	 classical	 intestinally-derived	 satiety	 hormones	 and	 leptin.	 However,	 GDF15	35	
levels	do	increase	following	sustained	high	fat	feeding	or	dietary	amino	acid	imbalance	in	mice.	We	36	
demonstrate	that	GDF15	expression	is	regulated	by	the	integrated	stress	response	and	is	induced	in	37	
selected	tissues	in	mice	in	these	settings.	Finally,	we	show	that	pharmacological	GDF15	administration	38	
	 2	
to	mice	can	trigger	conditioned	taste	aversion	suggesting	that	GDF15	may	induce	an	aversive	response	39	
to	nutritional	stress.		40	
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INTRODUCTION	45	
GDF15	 (growth	differentiation	 factor	15;	also	known	as	macrophage	 inhibitory	 cytokine-1	 (MIC-1),	46	
NAG1,	PLAB	and	PDF)	is	a	stress-induced	cytokine	and	an	atypical	member	of	the	transforming	growth	47	
factor	beta	superfamily	(Tsai	et	al.,	2016).	Bootcov	et	al	originally	characterised	it	as	a	dimeric	protein	48	
secreted	 by	 activated	macrophages	 (Bootcov	 et	 al.,	 1997).	 In	 healthy	 animals,	 it	 is	 predominantly	49	
expressed	 in	 the	 liver,	 lung	 and	 kidney	 and,	 at	 least	 in	 humans,	 in	 large	 amounts	 in	 the	 placenta	50	
(Böttner	et	al.,	1999;	Ding	et	al.,	2009;	Fairlie	et	al.,	1999;	Lawton	et	al.,	1997;	Marjono	et	al.,	2003;	51	
Yokoyama-Kobayashi	et	al.,	1997).	It	circulates	at	high	levels	in	humans	(Brown	et	al.,	2003;	Ho	et	al.,	52	
2012;	Kempf	et	al.,	2007;	Mullican	and	Rangwala,	2018)	and	serum	levels	are	known	to	increase	with	53	
age,	 smoking,	 intense	 exercise,	 cancer	 and	 a	 range	 of	 other	 disease	 states	 (reviewed	 in	 (Corre	 J,	54	
Hébraud	B,	2013;	Kleinert	et	al.,	2018;	Unsicker	et	al.,	2013)).	It	appears	that	almost	any	cell	or	tissue	55	
can	express	GDF15	in	response	to	various	forms	of		stress	(Appierto	et	al.,	2009;	Chung	et	al.,	2017;	56	
Hsiao	et	al.,	2000;	Park	et	al.,	2012;	Yang	et	al.,	2010).	The	measurement	of	circulating	concentrations	57	
of	GDF15	is	beginning	to	enter	clinical	practice	as	a	diagnostic	biomarker	in	mitochondrial	disease	and	58	
as	a	prognostic	marker	in	conditions	such	as	heart	failure	and	certain	cancers	(Fujita	et	al.,	2016;	Wang	59	
et	al.,	2013;	Wollert	et	al.,	2017).	60	
Johnen	et	al	first	reported	that	mice	bearing	tumours	engineered	to	over-express	GDF15	lost	weight	61	
dramatically	(Johnen	et	al.,	2007).	This	could	also	be	reproduced	by	injection	of	recombinant	GDF15	62	
and	 prevented	 by	 a	 neutralising	GDF15	 antibody.	 Transgenic	GDF15-expressing	mice	 similarly	 lost	63	
weight	secondary	to	reduced	food	intake	(Chrysovergis	et	al.,	2014;	Macia	et	al.,	2012).	Conversely,	64	
GDF15-null	mice	were	reported	to	be	slightly	heavier	(6-10%)	than	their	wildtype	littermates	(Tsai	et	65	
al.,	2013)	on	a	chow	diet,	a	difference	which	becomes	more	striking	on	a	high	fat	diet	(HFD)	(Tran	et	66	
al.,	2018).	GDF15	injection	induced	cFos	activation	in	selected	regions	of	the	brainstem,	particularly	67	
the	Nucleus	Tractus	Solitarius	(NTS)	and	AP	(Area	Postrema).	Selective	 lesioning	of	these	hindbrain	68	
regions	rendered	mice	unresponsive	to	the	anorexigenic	actions	of	GDF15	(Tsai	et	al.,	2014).	Recently,	69	
it	has	been	demonstrated	that	 these	effects	of	GDF15	are	mediated	via	a	 receptor	composed	of	a	70	
heterodimer	of	Ret		and	a	member	of	the	GDNF	receptor	alpha	(GFRa)	family,	known	as	GFRa-like	or	71	
GFRAL	 (Emmerson	et	al.,	2017;	Hsu	et	al.,	2017;	Mullican	et	al.,	2017;	Yang	et	al.,	2017).	Notably,	72	
GFRAL	 expression	 appears	 to	 be	 strictly	 confined	 to	 the	 AP	 and	NTS.	 In	 addition	 to	 reporting	 the	73	
structure	 of	 GFRAL,	 these	 papers	 also	 showed	 that	 GFRAL	 KO	mice	 are	 resistant	 to	 the	 anorectic	74	
effects	of	exogenous	injected	GDF15	and	to	endogenously	secreted	GDF15	levels	induced	by	cisplatin	75	
chemotherapy	 (Hsu	 et	 al.,	 2017),	 clearly	 establishing	 the	 GDF15-GFRAL	 axis	 as	 critical	 to	 stress	76	
pathway-induced	weight	loss.	Interestingly,	two	groups	also	noted	that	whereas	body	weight	is	similar	77	
to	that	of	wildtype	littermates	in	chow-fed	GFRAL-null	mice,	GFRAL-null	animals	gain	more	weight	on	78	
a	HFD	(Hsu	et	al.,	2017;	Mullican	and	Rangwala,	2018)	whereas	the	other	groups	reported	similar	body	79	
weights	in	GFRAL	null	mice	on	a	HFD	(Emmerson	et	al.,	2017;	Yang	et	al.,	2017).	It	is	unknown	whether	80	
circulating	levels	of	GDF15	rise	in	response	to	sustained	overfeeding	and,	if	this	occurs,	what	tisues	81	
are	responsible.	82	
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Here,	we	explore	the	relationship	between	GDF15	production	and	nutritional	state	and	find	that,	in	83	
contrast	to	enteroendocrine	hormones	or	 leptin,	GDF15	 levels	are	not	 influenced	by	meals,	by	the	84	
imposition	of	periods	of	caloric	deficit	or	caloric	excess	of	moderate	intensity	and	duration	in	mice	or	85	
humans.	However,	GDF15	levels	do	increase	significantly	when	mice	are	exposed	to	chronic	high	fat	86	
feeding.	We	then	characterise	in	detail	the	elements	of	the	cellular	integrated	stress	response	(ISR)	87	
that	 are	 involved	 in	 the	 regulation	 of	 GDF15	 expression	 and	 demonstrate	 activation	 of	 the	 ISR	 in	88	
selected	 tissues	 of	 high	 fat	 fed	mice.	We	 also	 show	 that	 another	 severe	 nutritional	 perturbation,	89	
namely	provision	of	a	lysine	deficient	diet	to	mice,	activates	the	ISR	and	increases	GDF15	levels.	Finally,	90	
we	provide	the	first	evidence	that	GDF15	generates	an	aversive	signal	through	the	demonstration	of	91	
conditioned	taste	aversion	in	mice.	92	
RESULTS	93	
GDF15	levels	are	unaffected	by	meals	or	glucose	ingestion	94	
It	is	well	established	in	humans	that	hormones	derived	from	enteroendocrine	cells	respond	to	acute	95	
changes	 in	nutritional	 state	 and	play	 a	 key	 role	 in	 regulating	energy	homeostasis.	 To	determine	 if	96	
GDF15	responds	 in	a	similar	way,	we	studied	the	response	of	humans	to	established	stimuli	of	the	97	
enteroendocrine	system.		98	
In	Human	study	1,	fasting	(overnight)	healthy	volunteers	received	a	mixed	macronutrient	liquid	drink	99	
(Figures	1A-D)	or	50	g	of	anhydrous	glucose	(Figures	S1A-D)	followed	by	30-minute	blood	sampling	for	100	
180	min.	In	both	studies,	glucose	peaked	at	30	minutes	(6.60	±	0.26	mmol/l	and	8.71	±	0.16	mmol/l,	101	
respectively),	with	a	lower	blood	glucose	in	the	mixed	macronutrient	load	reflecting	the	lower	sugar	102	
content	(22	g)	in	the	test	drink.	In	parallel	with	the	glucose	peak,	early	increases	in	both	insulin	and	103	
GLP-1	levels	were	observed	whereas,	circulating	GDF15	levels	briefly	(at	60	minute	timepoint)	fell	after	104	
the	mixed	meal	and	were	unchanged	following	glucose	ingestion,	as	reported	previously	(Tsai	et	al.,	105	
2015). 106	
GDF15	levels	in	response	to	an	imposed	caloric	deficit	107	
A	fall	in	the	adipose	derived	hormone,	leptin,	represents	an	important	peripheral	signal	of	nutritional	108	
deprivation,	serving	to	induce	hyperphagia	and	suppress	selected	neuroendocrine	hormone	axes.	To	109	
address	 the	question	of	whether	GDF15	mirrored	the	behaviour	of	 leptin	 to	changes	 in	nutritional	110	
state,	we	evaluated	the	response	of	circulating	GDF15	to	fasting	and	caloric	restriction	in	mice	and	111	
humans.		112	
First,	we	examined	hormone	responses	to	a	24	h	fast	in	mice	(Mouse	Study	1).	Despite	a	17.8	%	loss	113	
in	body	weight	and	a	marked	fall	in	leptin	levels,	circulating	levels	of	GDF15	were	unchanged	(Figures	114	
1E-G).		115	
Next,	circulating	GDF15	levels	were	measured	in	three	independent	studies	in	humans	subjected	to	116	
caloric	 restriction	 of	 varying	 intensity	 and	 duration.	 In	 Human	 Study	 2,	 GDF15	 concentrations	117	
increased	from	319.4	±	21.27	pg/ml	to	406.8	±	31.24	pg/ml	in	lean	healthy	volunteers	calorie	restricted	118	
for	2	days	(10	%	of	estimated	daily	energy	requirements)	(Figure	S1E).	119	
In	Human	 Study	 3,	 a	 cohort	 of	 obese	 participants	 consumed	 a	 low	 calorie	meal	 replacement	 diet	120	
(~1000	kcal/day)	for	28	days.	This	resulted	in	a	significant	reduction	in	body	weight	(-5.55	±	2.05	kg	121	
from	 baseline,	 p	 <0.0001;	 Figure	 1H)	 and	 leptin	 levels	 (Figure	 1I),	 whereas	 there	 was	 a	 small	122	
statistically	significant	increase	in	GDF15	levels	(Figure	1J).			123	
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In	Human	Study	4,	a	group	of	lean	healthy	participants	underwent	7	days	of	total	calorie	deprivation.	124	
As	expected,	circulating	leptin	levels	fell	precipitously	from	6.03	±	1.18	ng/ml	to	2.24	±	0.49	ng/ml	at	125	
24	h	(Figure	1K)	and	a	marked	ketogenic	response	(b-hydroxubutyrate)	was	observed	in	response	to	126	
the	 fast	 (Figure	 1L).	 Meanwhile,	 circulating	 GDF15	 levels	 increased,	 peaking	 at	 48	 h	 of	 caloric	127	
restriction	(from	371.4	±	94.2	pg/ml	at	baseline	to	670.2	±	349.2	pg/ml	p=0.003).	Interestingly,	despite	128	
continuation	 of	 the	 calorie	 deprivation,	 GDF15	 levels	 gradually	 returned	 towards	 baseline	 levels	129	
although	remained	higher	than	starting	values	(441.2	±	151.3	pg/ml)	(Figure	1M).		130	
From	 these	 studies	 in	 both	mice	 and	humans,	 it	 is	 clear	 that	GDF15	does	not	 exhibit	 a	 leptin-like	131	
response	to	caloric	restriction.	Rather,	a	small	increase	in	GDF15	levels	is	observed	under	conditions	132	
of	severe	nutritional	deprivation.		133	
GDF15	in	response	to	short-term	hypercaloric	loads		134	
In	 contrast	 to	 caloric	 deprivation,	 states	of	 nutritional	 excess	 and	weight	 gain	 are	 associated	with	135	
physiological	increases	in	leptin.	We	studied	the	effect	of	short-term	hyper-caloric	interventions	on	136	
non-obese	volunteers	to	determine	if	they	had	a	similar	effect	on	GDF15.		137	
In	Human	Study	5,	we	assessed	changes	in	GDF15	in	healthy	volunteers	in	response	to	short-term	high	138	
fat	overfeeding.	After	7	days	of	the	intervention,	a	significant	increase	in	body	weight	was	observed	139	
(1.64	±	1.07	kg,	p	<0.0001)	compared	to	baseline	(Figure	S1F)	accompanied	by	a	significant	increase	in	140	
leptin	levels	(Figure	S1G).	Despite	the	observed	increases	in	fasting	insulin	and	glucose	levels	(Figure	141	
S1H	and	S1I),	there	was	no	significant	change	in	median	(IQR)	GDF15	levels	(302.0	(256.0-318.0)	pg/ml	142	
(baseline)	vs.	295.0	(258.0-343.5)	pg/ml	(after	overfeeding))	(Figure	S1J).	143	
Human	Study	6	examined	the	effect	of	an	8	week	overfeeding	intervention	(additional	40	%	of	weight	144	
maintenance	energy	requirements)	on	healthy	participants	 in	an	 inpatient	setting.	This	produced	a	145	
significant	increase	in	weight	(5.52	±	2.05	kg,	p<0.0001)	and	leptin	levels	(Figures	S1K	and	S1L),	but	no	146	
rise	in	circulating	GDF15.	Indeed	at	the	end	of	the	intervention,	GDF15	levels	were	actually	lower	than	147	
at	entry	to	the	study	(Figure	S1M).			148	
Consistent	with	these	data,	GDF15	levels	were	unchanged	in	mice	fed	a	high	fat	diet	for	up	to	seven	149	
days	(Mouse	Study	2),	despite	the	mice	manifesting	the	anticipated	increases	in	fat	and	liver	weight,	150	
and	rises	in	plasma	insulin	and	leptin	(Figure	S2).		151	
	152	
Taken	 together	 these	 data	 suggest	 that,	 unlike	 established	 hormonal	 regulators	 of	 energy	153	
homeostasis,	“modest”	overfeeding	in	humans	and	mice	does	not	trigger	GDF15	production.		154	
	155	
GDF15	levels	are	increased	by	sustained	hypercaloric	loads		156	
As	 GDF15	 is	 a	 stress-responsive	 hormone,	 we	 wondered	 if	 more	 prolonged	 or	 severe	 nutritional	157	
stressors	 might	 be	 needed	 to	 induce	 its	 expression	 and	 secretion.	 To	 test	 this	 hypothesis,	 we	158	
undertook	a	prospective	longitudinal	study	in	mice	fed	either	a	chow	(CD)	or	high-fat	diet	(HFD)	from	159	
9	weeks	of	age	(Mouse	Study	3).	This	resulted	in	progressive	weight	gain	and	fat	mass	in	association	160	
with	 rising	 insulin	 and	 leptin	 levels	 (Figures	 2A-D).	 Glucose	 levels	were	 initially	 similar	 in	 the	 two	161	
groups	 but	 rose	 significantly	 in	 the	HFD	 fed	mice	 from	week	 4	 onwards	 (Figure	 2E).	GDF15	 levels	162	
started	to	rise	at	the	4	week	time	point	and	were	significantly	higher	in	the	HFD	fed	mice	from	week	163	
8	onwards	(Figure	2F).	164	
In	order	to	clarify	the	source	of	GDF15	in	this	context,	we	analysed	GDF15	mRNA	expression	in	a	range	165	
of	tissues.	GDF15	expression	increased	in	liver,	white	epididymal	-	and	even	more	strikingly	in	brown	166	
	 5	
adipose	tissue,	but	not	in	subcutaneous	inguinal	fat,	kidney	and	skeletal	muscle	(expression	was	very	167	
low	in	the	latter)	(Figure	2G).	168	
GDF15	expression	is	regulated	by	the	cellular	integrated	stress	response.		169	
Next	we	sought	to	establish	why	GDF15	expression	was	induced	in	these	tissues	in	this	context.	Prior	170	
work	 had	 suggested	 that	 ATF4	 and	 CHOP,	 key	 transcriptional	 regulators	 of	 the	 integrated	 stress	171	
response	 (ISR)	might	 be	 involved	 (Suzuki	 et	 al.,	 2017).	 The	 ISR	 is	 a	 cell	 autonomous	 integrator	 of	172	
diverse	cellular	stresses,	so	we	began	by	documenting		changes	in	GDF15	mRNA		in	mouse	embryonic	173	
fibroblasts	 (MEFs)	 treated	 with	 a	 range	 of	 well-characterised	 stressors	 (Figure	 3).	 These	 included	174	
cobalt	chloride,	a	chemical	mimic	of	hypoxia,	which	acts	by	stabilising	hypoxia	inducible	factor	1a	(HIF-175	
1a);	unfolded	protein	response	(UPR)-inducers	thapsigargin,	an	inhibitor	of	sarcoplasmic/endoplasmic	176	
reticulum	Ca2+-ATPase	(SERCA)	and	tunicamycin,	an	inhibitor	of	N-linked	glycosylation,	both	of	which	177	
perturb	protein	folding;	and	histidinol,	an	inhibitor	of	histidyl	tRNA	synthetase	which	mimics	amino	178	
acid	 deprivation.	 All	 these	 agents	 caused	 a	 significant	 and	 robust	 induction	 of	 GDF15	 mRNA	179	
expression,	albeit	to	varying	extents,	with	thapsigargin	being	the	most	potent	(Figure	3A).	To	confirm	180	
that	GDF15	can	be	similarly	upregulated	in	other	cell	types,	we	documented	stress-induced	changes	181	
in	GDF15	expression	in	a	range	of	human	cell	lines,	as	well	as	in	3T3-L1	preadipocytes	(Figure	3B	and	182	
Figures	S3A-C).	In	each	case,	GDF15	expression	was	increased	with	the	level	of	induction	ranging	from	183	
2-30	fold.	184	
	185	
All	of	the	stress-inducing	agents	used	here	can	trigger	phosphorylation	of	EIF2a	by	one	of	four	known	186	
EIF2a	kinases	(Harding	et	al.,	2000b,	2000a;	Koumenis	et	al.,	2002;	Taniuchi	et	al.,	2016),	so	we	went	187	
on	to	confirm	that	this	did	occur	at	the	concentrations	and	over	the	time	frames	used	in	our	study	188	
(Figure	3C).	Indeed,	in	addition	to	the	stress-induced	phosphorylation	of	EIF2a at	Ser51,	the	protein	189	
expression	 of	 both	 the	 downstream	 targets,	 ATF4	 and	 CHOP,	was	 increased,	 albeit	 to	 a	 different	190	
extent,	with	tunicamycin	and	thapsigargin	being	the	most	potent	inducers.		191	
Next,	we	used	a	combination	of	inhibitors	and	knockout-	or	knockdown	MEF	lines	to	test	the	roles	of	192	
various	 elements	 of	 the	 ISR	 pathway	 in	 the	 regulation	 of	GDF15.	 Firstly,	 using	 the	 PERK	 inhibitor,	193	
GSK2606414	(abbreviated	as	GSK	in	Figure	1),	or	the	EIF2a inhibitor,	ISRIB	(abbreviated	as	ISR	in	Figure	194	
1),	we	demonstrated	 that	 the	 tunicamycin-mediated	 induction	of	GDF15	was	 significantly	 reduced	195	
(Figure	3D),	and	that	this	correlated	with	a	reduction	in	the	activation	of	the	ISR	pathway,	as	judged	196	
by	decreased	ATF4	and	CHOP	expression	(Figure	S3D).		We	also	found	that	the	tunicamycin-induced	197	
expression	of	GDF15	was	abolished	in	MEFs	harbouring	a	mutation	at	the	key	phosphorylation	site	on	198	
EIF2a	 (Ser51-Ala)	 required	 for	 ISR	 activation	 (Figure	 3E).	 Similarly,	 moving	 downstream	 in	 the	199	
pathway,	 tunicamycin-induced	GDF15	expression	was	abolished	 in	ATF4	knockout	MEFs	 (Figure	3F	200	
and	Figure	S3E).		Furthermore,	siRNA-mediated	knockdown	of	CHOP	significantly	reduced	both	basal	201	
and	tunicamycin-induced	GDF15	expression	(Figure	3G	and	Figure	S3F).	Coupled	with	the	knowledge	202	
that	 circulating	 GDF15	 acts	 via	 GFRAL	 in	 the	 hindbrain,	 establish	 GDF15	 as	 a	 bona	 fide	 systemic	203	
endocrine	signal	of	the	ISR.	204	
In	order	to	establish	if	the	ISR	is	indeed	responsible	for	the	observed	induction	of	GDF15	in	long-term	205	
HF	 fed	mice,	we	next	evaluated	expression	of	ATF4	and	CHOP	mRNA	 in	 the	same	panel	of	 tissues	206	
assessed	for	GDF15	expression	(Mouse	Study	3).	These	data	confirmed	that	ATF4	and	CHOP	mRNA	207	
were	 increased	 in	 the	 liver	 and	 BAT	 (ATF4	 only),	 but	 interestingly	 not	 in	 WAT	 (Figure	 S3G,	 H),	208	
suggesting	that	the	induction	of	GDF15	in	WAT	may	involve	other	signalling	pathways.	HF	feeding	in	209	
mice	 leads	to	adipocyte	cell	death,	particularly	 in	epididymal	fat	(Strissel	et	al.,	2007),	and	this	has	210	
been	shown	to	activate	macrophages	(Cinti	et	al.,	2005).	Furthermore,	GDF15	was	originally	identified	211	
in	activated	macrophages	 (Bootcov	et	al.,	1997),	 so	we	proceeded	to	check	mRNA	expression	of	a	212	
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macrophage	marker,	F4/80,	in	the	white	and	brown	adipose	tissue	samples.		F4/80	mRNA	increased	213	
in	parallel	with	the	changes	in	GDF15	mRNA	(Figure	S3I),	so	we	sought	to	establish	if	GDF15	mRNA	214	
was	 being	 induced	 in	macrophages,	 or	 other	 stromovascular	 fraction	 (SVF)	 cells,	 or	 in	 adipocytes	215	
themselves.	The	data	suggest	that	GDF15	mRNA	is	induced	in	both	fractions	(Figure	S3J).	However,	216	
lipid	 laden	macrophages	may	 ‘contaminate’	 the	 adipocyte	 fraction	 as	 the	 separation	 is	 based	 on	217	
flotation	so	we	went	on	to	check	for	this	by	analysing	mRNA	expression	of	Plin1	(an	adipocyte	marker)	218	
and	F4/80	in	each	of	the	fractions.	These	data	suggest	that	macrophages	are	present	in	the	adipocyte	219	
fraction	 so	 it	 remains	 possible	 that	 the	 apparent	 increase	 in	GDF15	mRNA	 is	 largely	 coming	 from	220	
macrophages,	though	we	cannot	formally	exclude	a	contribution	from	adipocytes	themselves.		221	
From	 these	 data,	 it	 is	 clear	 that	 in	mice,	 GDF15	 expression	 is	 responsive	 to	 chronic	 conditions	 of	222	
overnutrition	that	manifest	with	changes	in	GDF15	within	adipose	tissue	(white	and	brown)	and	the	223	
liver.	These	findings	are	consistent	with	reported	increases	in	GDF15	levels	in	ob/ob	mice	and	in	obese	224	
humans	 (Dostálová	 et	 al.,	 2009;	 Xiong	 et	 al.,	 2017),	 though	 the	 latter	 will	 require	 further	 careful	225	
analysis	as	Tsai	et	al	(Tsai	et	al.,	2015)	reported	that	in	non-obese	monozygotic	twin	pairs	(n=72	pairs),	226	
the	twin	with	the	higher	GDF15	concentration	had	a	lower	BMI.		227	
GDF15	levels	in	response	to	an	amino	acid	imbalanced	diet		228	
Having	demonstrated	that	nutritional	overload	can	induce	GDF15	expression,	we	wondered	if	other	229	
nutritional	stresses	might	have	similar	consequences.		Previous	studies	have	shown	that	diets	deficient	230	
in	essential	amino	acids	can	influence	food	intake	and	increase	FGF21	levels	in	an	ATF4	dependent	231	
manner	(Gietzen	et	al.,	2016;	De	Sousa-Coelho	et	al.,	2012,	2013),	so	we	wondered	if	such	diets	might	232	
have	a	comparable	impact	on	GDF15	levels.	This	was	of	particular	relevance	as	we	had	shown	(Figure	233	
3A)	 that	 pharmacological	mimics	 of	 amino	 acid	 imbalance	which	 activate	 the	 ISR,	 increase	GDF15	234	
expression	in	cells.	To	test	this	hypothesis,	mice	were	fasted	overnight	and	then	fed	a	lysine	deficient	235	
diet	for	4	h	(Mouse	Study	4).	This	led	to	a	marked	increase	in	circulating	GDF15	levels	compared	to	236	
chow	fed	animals	(Figure	4A).	 In	keeping	with	activation	of	the	 ISR,	ATF4,	CHOP	and	GDF15	mRNA	237	
were	all	significantly	increased	in	the	livers	of	these	mice	(Figures	4B-D).		238	
GDF15	administration	results	in	conditioned	taste	aversion	239	
Reduced	food	intake	has	been	shown	to	mediate	most	of	the	effects	of	GDF15	administration	or	over-240	
expression	on	body	weight	(Emmerson	et	al.,	2017;	Macia	et	al.,	2012;	Mullican	et	al.,	2017;	Yang	et	241	
al.,	 2017).	 Activation	 of	 the	 GDF15	 receptor	 (GFRAL)	 has	 also	 been	 linked	 to	 subsequent	 cFos	242	
activation	in	the	parabrachial	nucleus	(PBN)	which	has	in	turn	been	linked	to	appetite	suppression	in	243	
response	to	meal-related	peptides,	as	well	as	ingestion	of	toxins,	mimicked	by	lithium	chloride	and	244	
lipopolysaccharide	 (Carter	 et	 al.,	 2013;	 Hsu	 et	 al.,	 2017).	 Thus	 we	 hypothesized	 that	 GDF15	245	
administration	 might	 result	 in	 conditioned	 taste	 aversion	 (CTA),	 which	 occurs	 when	 an	 animal	246	
associates	 the	 taste	 of	 a	 normally	 favoured	 food	 with	 symptoms	 caused	 by	 a	 concomitantly	247	
administered	toxic	or	aversive	substance.	248	
In	Mouse	Study	5,	 	we	 first	 assessed	 the	ability	of	GDF15	 to	 lower	 food	 intake	 in	 a	 concentration	249	
dependent	manner.	A	single	subcutaneous	injection	of	GDF15	in	mice	acutely	increased	plasma	GDF15	250	
concentration,	with	maximum	exposures	occurring	1	and	4	hours	post-treatment	(Figure	4E).	GDF15	251	
treatment	 resulted	 in	 a	 corresponding	 dose-dependent	 reduction	 of	 food	 intake	 which	 reached	252	
statistical	 significance	at	 the	highest	dose	 (0.1	mg/kg)	 (Figures	4F,G).	We	 then	addressed	whether	253	
GDF15	induced	conditioned	taste	aversion	behavior	using	the	two	bottle	saccharin	preference	test.	254	
Similar	to	the	positive	CTA	control,	lithium	chloride,	GDF15	treatment	at	0.01	mg/kg	and	0.1	mg/kg	255	
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also	reduced	saccharin	consumption	and	increased	water	consumption	compared	to	vehicle	control	256	
(Figure	4H).		257	
This	data	demonstrates	that	acute	administration	of	GDF15	can	elicit	an	aversive	response	in	rodents.	258	
Nutritional	regulation	of	FGF21	expression		259	
Although	 its	physiological	 function	 in	humans	 is	not	 clearly	established,	 FGF21	 is	 another	putative	260	
systemic	signal	induced	by	the	ISR	(Fisher	and	Maratos-Flier,	2016;	Salminen	et	al.,	2017).	In	humans,	261	
plasma	FGF21	levels	did	not	change	significantly	following	a	mixed	meal	or	oral	glucose	challenge,	a	262	
week	of	total	calorie	restriction	or	high	fat	overfeeding	in	healthy	volunteers	(Figures	S4A-D).	In	mice,	263	
short	term	overfeeding	 induced	a	small	 increase	 in	FGF21	 levels	whereas	prolonged	HFD	exposure	264	
was	associated	with	a	robust	increase	in	FGF21	levels	(Figures	S4E,F).	Interestingly,	although	FGF21	265	
mRNA	increased	in	similar	tissues	as	GDF15,	within	WAT,	FGF21	seemed	to	originate	from	adipocytes	266	
themselves	 rather	 than	 macrophages	 (Figures	 5G,H).	 Lysine-deficient	 diet	 in	 mice	 also	 elicited	 a	267	
significant	increase	in	hepatic	FGF21	mRNA	(Figures	S4I).	In	cells,	FGF21	responses	to	activation	of	the	268	
ISR	 largely	 mirrored	 the	 GDF15	 responses	 with	 one	 notable	 exception;	 that	 being	 exaggerated	269	
induction	rather	than	amelioration	of	the	FGF21	response	to	TN	in	CHOP	knockdown	cells	(Figures	S4J-270	
N).	 These	 results	 suggest	 that	 whilst	 the	 ISR	 pathway	 regulates	 both	 hormones,	 the	 molecular	271	
mechanisms	 downstream	 of	 ATF4	 are	 distinct.	 These	 data	were	 corroborated	 by	 the	 finding	 that	272	
circulating	FGF21	and	hepatic	FGF21	mRNA	levels	were	significantly	increased	in	mice	following	a	24	273	
hour	fast,	despite	the	lack	of	a	significant	change	in	ATF4	or	CHOP	mRNA	expression	(Figures	S4O-R).	274	
Fasting	 induced	FGF21	expression	 is	 known	 to	 involve	PPARa	 (Badman	et	 al.,	 2007;	 Inagaki	 et	 al.,	275	
2007).		 	276	
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DISCUSSION	277	
Elevating	GDF15	levels	by	transgenic	over-expression	(Chrysovergis	et	al.,	2014;	Macia	et	al.,	2012)	or	278	
pharmacological	administration	in	mice	and	non	human	primates	leads	to	a	marked	fall	in	body	weight	279	
(Mullican	et	al.,	2017).	The	principal	aim	of	our	work	was	to	understand	if	and	how	GDF15	might	be	280	
involved	 in	 physiological	 settings	 of	 under-	 and	 over-nutrition.	 To	 this	 end	 we	 combined	 cellular	281	
studies	with	in	vivo	work	in	mice	and	humans	to	establish	that	GDF15	expression	is	highly	responsive	282	
to	activation	of	the	integrated	stress	response	in	a	range	of	cell	types	and	that	 its	 induction	in	this	283	
setting	 is	dependent	upon	ATF4	and	CHOP.	The	 idea	that	cellular	stress	might	be	translated	 into	a	284	
systemic	response	initially	emerged	from	work	in	C.elegans	where	an	induction	of	the	mitochondrial	285	
unfolded	 protein	 response	 (UPRmt)	 in	 neurons	 led	 to	 changes	 in	 mitochondria	 within	 physically	286	
distinct,	 non-innervated	 tissues	 (Durieux	 et	 al.,	 2011),	 but	 has	 more	 recently	 been	 supported	 by	287	
evidence	linking	FGF21	to	the	integrated	stress	response	(Salminen	et	al.,	2017).	Chung	et	al	(Chung	288	
et	al.,	2017)	also	recently	proposed	that	GDF15	could	act	as	a	‘mitohormetic’	signal	of	mitochondrial	289	
dysfunction.	Our	analysis	 is	 largely	consistent	with	these	data	and	provides	compelling	evidence	of	290	
the	induction	of	GDF15	in	response	to	activation	of	the	ISR.		291	
As	GDF15	administration	causes	weight	loss	and	mice	lacking	GDF15	are	prone	to	gain	weight	on	a	292	
high-fat	diet,	we	determined	whether	GDF15	shares	any	features	in	common	with	known	hormonal	293	
regulators	 of	 post-prandial	 satiety	 (e.g	 enteroendocrine	 hormones	 such	 as	 GLP-1)	 or	 longer	 term	294	
hormonal	regulators	of	nutrient	stores	(e.g	leptin).	In	contrast	to	GLP-1,	and	consistent	with	previous	295	
reports,	(Schernthaner-Reiter	et	al.,	2016;	Tsai	et	al.,	2015)	GDF15	did	not	respond	acutely	to	a	meal	296	
or	 a	 glucose	 load	 in	 humans.	 In	mice	 fasted	 for	 24	 h,	 there	was	 no	 change	 in	 circulating	 GDF15,	297	
whereas	the	predicted	fall	in	leptin	levels	and	rise	in	FGF21	levels	was	seen.	In	humans,	48	h	of	severe	298	
caloric	 restriction	 in	 lean	 healthy	 volunteers	 resulted	 in	 a	 significant	 but	 small	 increase	 in	 GDF15	299	
concentrations.	 In	 healthy	 volunteers	 undergoing	 a	 seven	 day	 total	 fast,	 GDF15	 levels	 peaked	 at	300	
around	~180	%	of	baseline	by	day	3	and	then	plateaued	at	around	118	%	at	day	7.	This	early	rise	in	301	
GDF15	is	in	the	opposite	direction	expected	of	a	physiological	regulator	of	energy	balance	and	is	more	302	
consistent	with	GDF15	being	a	marker	of	cell/tissue	stress.	The	mechanisms	whereby	GDF15	levels	303	
start	to	return	towards	baseline	with	more	prolonged	fasting	are	unknown,	but	presumably	reflect	304	
some	sort	of	adaptation	to	the	starved	state.		305	
In	two	separate	studies,	overfeeding	of	healthy	humans	with	a	~48	%	excess	of	ingested	calories	for	1	306	
week,	 or	 40	%	 for	 8	weeks	 did	 not	 increase	 GDF15	 concentrations.	 Of	 note,	 in	 the	 longer	 study,	307	
conducted	in	an	inpatient	setting,	GDF15	levels	showed	a	small	but	significant	fall	(Figure	S1M).	Among	308	
possible	explanations	for	this	fall	is	the	fact	that	in	this	inpatient	study,	smoking	was	not	permitted.	309	
GDF15	levels	are	known	to	be	positively	associated	with	smoking	status	and	it	is	possible	that	some	310	
participants	quit	smoking	just	prior	to	the	study	(Ho	et	al.,	2012;	Wu	et	al.,	2012).		311	
In	contrast	to	the	studies	summarised	above,	we	found	that	circulating	GDF15	levels	rose	in	long-term	312	
high	fat	feeding	studies	in	mice.	Whether	or	not	this	is	also	true	in	humans	will	require	further	studies.	313	
As	 recently	 summarised	 by	 Tsai	 et	 al,	 the	 relationship	 between	 circulating	 GDF15	 and	 obesity	 in	314	
humans	 is	 complex.	 GDF15	 levels	 rise	 with	 age	 and	 are	 also	 induced	 by	 conditions	 commonly	315	
associated	with	obesity	such	as	diabetes	and	cardiovascular	disease	(Tsai	et	al.,	2018;	Wollert	et	al.,	316	
2017).	So,	whilst	positive	correlations	between	GDF15	and	measures	of	adiposity	have	been	reported	317	
in	several	small	studies	(Dostálová	et	al.,	2009;	Ho	et	al.,	2012;	Karczewska-Kupczewska	et	al.,	2012;	318	
Kempf	et	al.,	2012;	Vila	et	al.,	2011),	GDF15	was	shown	to	be	inversely	correlated	with		BMI	in	non-319	
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obese	monozygotic	twin	pairs	(Tsai	et	al.,	2015).	It	is	plausible	that	an	inherent	genetically	determined	320	
increase	in	GDF15	levels	or	one	induced	by	another	cell	stressor/	disease	might	result	in	weight	loss,	321	
and	thus	confound	straightforward	correlations	between	BMI	and	GDF15	levels.		322	
Ravussin	et	al	have	drawn	attention	to	the	likely	existence	of	leptin-independent	signals	of	the	obese	323	
state	that	might	serve	to	restrain	the	indefinite	progression	of	a	state	of	positive	energy	balance	and	324	
ever	increasing	obesity	(Ravussin	et	al.,	2014).	The	fact	that	mice	lacking	GDF15	become	more	obese	325	
on	a	high	fat	diet	than	wildtype	mice	suggests	that	GDF15	might	at	least	contribute	to	that	signal	(Hsu	326	
et	al.,	2017;	Tran	et	al.,	2018).	Our	studies	show	that	while	short-term	overfeeding	does	not	increase	327	
GDF15,	more	sustained	states	of	caloric	excess	will	raise	circulating	GDF15	levels.		328	
What	is	the	source	of	the	elevated	levels	of	the	GDF15	seen	in	the	overnourished	state?	In	mice,	GDF15	329	
mRNA	is	increased	in	liver	and	BAT,	and	in	certain	white	adipose	tissue	depots,	such	as	epididymal,	by	330	
18	weeks	of	HFD,	but	not	in	kidney	or	muscle.	 In	adipose	tissue	it	appears	that	most	of	the	GDF15	331	
mRNA	is	likely	to	be	coming	from	infiltrating	macrophages,	whereas	our	initial	analyses	suggest	that	332	
FGF21	mRNA	is	more	robustly	induced	in	adipocytes	themselves.		Macrophages	are	frequently	cited	333	
as	mediating	many	of	the	adverse	metabolic	consequences	of	overnutrition	such	as	insulin	resistance,	334	
through	their	production	of	a	range	of	cytokine	like	molecules.	In	the	case	of	GDF15,	it	appears	that	335	
these	cells	produce	a	circulating	product	which	in	this	particular	context	might	be	beneficial	to	the	336	
organism.		337	
We	also	show	GDF15	is	significantly	induced	by	another	nutritional	stress,	namely	a	lysine	deficient	338	
diet.	Interestingly,	involvement	of	the	ISR	in	response	to	perturbations	affecting	amino	acid	provision,	339	
is	conserved	as	far	back	as	yeast	(Hinnebusch,	2005),	where	the	response	is	clearly	cell	autonomous.	340	
In	metazoans,	this	response	expanded	to	encompass	rectifying	responses	to	other	cell	autonomous	341	
perturbations	 such	 as	 the	 unfolded	 protein	 response,	 hypoxia,	 viral	 infections	 and	 iron	 deficiency	342	
(Pakos-Zebrucka	et	al.,	2016).	The	link	to	the	GDF15-GFRAL	axis	suggests	that	the	ISR	may	now	also	343	
have	gained	an	endocrine	component	potentially	involving	an	aversive	response	instructing	the	animal	344	
to	change	its	foraging	pattern.	In	some	settings	this	is	likely	to	be	advantageous	to	the	animal	though	345	
there	are	clearly	exceptions	where	it	is	not,	such	as	in	cancer	cachexia,	where	GDF15	levels	can	be	as	346	
high	as	40,000	pg/ml	(Johnen	et	al.,	2007;	Welsh	et	al.,	2003).		347	
What	then	are	the	consequences	of	 induction	of	 this	hormone?	GDF15	has	been	shown	to	reduce	348	
food	intake	in	various	species	and	to	alter	food	choice.	While	it	has	been	speculated	that	GDF15	may	349	
produce	an	aversive	response	(O’Rahilly,	2017)	this	had	not	previously	been	formally	demonstrated.																																																																																																																																																				350	
Using	 a	 conditioned	 taste	 aversion	 (CTA)	 paradigm,	 we	 show	 that	 mice	 exposed	 to	 GDF15	 in	351	
association	with	a	saccharin	taste	will	avoid	saccharin	containing	drinking	water	in	future	exposures.	352	
CTA	is	classically	elicited	by	injection	of	Lithium	Chloride	and	is	also	typical	of	agents	that	are	known	353	
to	produce	nausea	in	humans.	In	this	context,	GDF15	contrasts	with	leptin	which	reduces	food	intake	354	
but	 does	 not	 produce	 CTA	 (Thiele	 et	 al.,	 1997).	 The	 lateral	 parabrachial	 nucleus	 (PBN),	 medial	355	
thalamus,	and	basolateral	nucleus	of	the	amygdala	are	essential	for	both	acquisition	and	retention	of	356	
CTA	with	CGRP	expressing	neurons	of	 the	parabrachial	nucleus	playing	an	essential	 role	 (Palmiter,	357	
2018).	Ascending	pathways	from	the	AP	and	NTS	make	substantial	connections	to	the	lateral	PBN.	It	358	
Is	therefore	likely,	though	yet	to	be	formally	established,	that	GFRAL	expressing	neurons	of	the	caudal	359	
hindbrain	project	to	the	PBN.		360	
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In	summary,	GDF15	appears	to	be	an	endocrine	signal	which	can	be	produced	by	almost	any	cell	type	361	
in	response	to	activation	of	the	 integrated	stress	response	and	presumably	other	signals.	Our	data	362	
suggests	 that	 ‘nutritional	 stress’	 whether	 induced	 by	 sustained	 overnutrition	 as	 exemplified	 by	363	
prolonged	high	fat	feeding	in	mice	or	by	provision	of	an	amino	acid	imbalanced	diet	leads	to	increased	364	
circulating	GDF15	levels.	We	suggest	that	this	might	send	an	aversive	endocrine	signal	to	the	brain,	365	
though	we	acknowledge	that	further	work	is	needed	to	verify	this	hypothesis.	If	GDF15	is	playing	a	366	
role	 in	 restraining	progressive	weight	gain	 this	suggests	 that	 it	might	have	a	role	 in	 the	therapy	of	367	
obesity.	While	 its	production	of	conditioned	taste	aversion	might	seem	to	suggest	that	 it	would	be	368	
poorly	tolerated	in	humans,	it	is	premature	to	conclude	that	this	should	prevent	its	exploration	as	a	369	
possible	obesity	therapeutic.	GLP-1	based	drugs	are	licensed	for	the	treatment	of	obesity	yet	they	too	370	
produce	a	CTA	 response	 in	 rodents	and	activate	 the	 lateral	PBN	 (Thiele	et	al.,	 1997).	With	 careful	371	
titration,	most	humans	can	tolerate	therapeutic	doses	of	GLP-1	receptor	agonists,	though	nausea	and	372	
vomiting	do	 lead	 to	 its	 cessation	 in	a	 significant	number.	Thus	 these	data	 support	 the	burgeoning	373	
interest	in	GFRAL,	the	GDF15	receptor,	as	an	attractive	therapeutic	target	in	so	far	as	it	has	a	highly	374	
tissue	specific	expression	with	actions	of	GDF15	at	sites	other	than	the	caudal	brain	stem	seemingly	375	
unlikely.	Studies	of	the	effects	of	GDF15	in	humans	are	eagerly	anticipated.	376	
	377	
Limitation	of	Study	378	
Limitations	 of	 our	 studies	 include	 the	 fact	 that	 whilst	 we	 have	 shown	 that	 high	 fat	 and	 lysine	379	
deficient	diets	can	induce	GDF15,	and	that	when	administered	at	pharmacological	doses,	GDF15	can	380	
induce	an	aversive	response,	we	have	yet	to	formally	demonstrate	that	this	also	occurs	when	GDF15	381	
is	induced	endogenously.	One	might	also	argue	that	the	small	increases	in	GDF15	we	detected	in	382	
response	to	extreme	fasting	 in	humans	 is	counter-intuitive,	however,	we	speculate	that	 in	these	383	
circumstances,	in	addition	to	causing	food	aversion,	GDF15	might	also	cause	malaise,	which	might	384	
encourage	an	animal	to	rest	and	conserve	energy.		385	
	386	
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FIGURE	LEGENDS	645	
Figure	1:	GDF15	levels	in	response	to	a	meal	or	imposed	caloric	deficit	in	mice	and	humans.	646	
HS1-Human	Study	1	(A-D):	Plasma	(A)	glucose,	(B)	Insulin,	(C)	GLP-1	and	(D)	GDF15	circulating	levels	647	
in	six	healthy	volunteers	given	an	oral	mixed	macronutrient	liquid	meal	following	an	overnight	fast.	648	
Blood	samples	were	taken	over	the	180	min	duration	of	the	study.		Data	is	expressed	as	mean	±	SEM.	649	
*	p	<0.05,	**	p	<	0.01,	***p	<	0.001	comparing	to	Time	0	min	by	a	One-way	ANOVA	with	Bonferroni	650	
post-test.		651	
MS1-Mouse	Study	1	(E-G):	(E)	Body	weight	of	mice	before	and	after	a	24	h	fasting	challenge	(n=5	mice).	652	
(F)	Leptin	and	(G)	GDF15	serum	concentrations	in	11-12-week-old	male	mice	either	in	the	fed	state	or	653	
after	a	24	h	fast.	Data	is	expressed	as	mean	±	SEM	(n	=	5	mice	per	group).	***p	<	0.001	by	Two	tailed	654	
Student	T-Test.	Note	all	fasted	leptin	values	were	under	the	detection	limit	(0.033	ng/ml).	655	
HS3-Human	study	3	(H-J):	(H)	Body	weight,	(I)	leptin	and	(J)	GDF15	levels	in	a	cohort	of	overweight	and	656	
obese	participants	subjected	to	caloric	restriction	(~1000	kcal/day)	 for	a	period	of	28	days.	Data	 is	657	
from	33	participants,	expressed	as	mean	±	SEM.	*	p	<0.05,	****p	<	0.0001	by	a	One-way	ANOVA	with	658	
Bonferroni	multiple	comparison	post-test	(for	body	weight	and	leptin),.		659	
HS4-Human	study	4	(K-M):	(K)	Leptin,	(L)	b-hydroxybutyrate	and	(M)	GDF15	levels	in	human	volunteers	660	
subjected	to	a	7-day	fast	(0	kcal	per	day).	Data	is	from	13	participants,		expressed	as	mean	±	SEM	and	661	
analysed	by	a	One-way	ANOVA.	In	the	case	of	GDF15,	values	are	expressed	as	median	(interquartile	662	
range).		***	p	<	0.001,	****	p	<	0.0001	by	a	Kruskal-Wallis	test.	Also	see	Figures	S1	and	S4.	663	
	664	
Figure	2.	GDF15	is	upregulated	by	long-term	high	fat	feeding	in	mice.	665	
MS3-Mouse	Study	3:	C57Bl/6J	male	mice	(aged	9	weeks)	were	fed	a	chow	(CD)	or	high	fat	diet	(HFD)	666	
for	16	weeks.	(A)	Body	weight	was	recorded	weekly	(CD	n=7	and	HFD	n=8),	while	(B)	fat	mass	and	(C)	667	
insulin,	(D)	leptin,	(E)	glucose	and	(F)	GDF15	concentrations	were	determined	at	0,	4,	8,	12	(CD	n=9-668	
11;	HFD	n=10-12)	and	16	weeks	(CD	n=7;	HFD	n=8)	(all	after	a	4	h	fast).	Data	is	expressed	as	mean	±	669	
SEM.	*	p	<0.05,	**	p	<	0.01,	***p	<	0.001,	****p	<	0.0001	by	Two	way	ANOVA	with	Bonferroni	multiple	670	
comparison	post	test.	The	red	asterisks	in	(D)	denote	time-points	at	which	some	(1	out	of	12	at	12	671	
weeks	and	3	out	of	8	at	16	weeks)	leptin	values	were	above	the	assay	detection	limit	(>100	ng/ml)	and	672	
thus	were	set	at	100	ng/ml.		673	
(G)	GDF15	mRNA	expression	 in	subcutaneous	 -	 (SAT),	epididymal	 -	 (EAT)	and	brown	(BAT)	adipose	674	
tissue,	liver,	soleus	muscle	and	kidney	isolated	from	C57Bl/6J	male	mice	fed	a	CD	or	HFD	for	18	weeks	675	
(n=6-8	mice/group).	mRNA	 is	presented	as	 fold-expression	 (mean	±	SEM)	 relative	 to	 the	chow	 fed	676	
state	from	muscle	(set	at	1)	and	normalised	to	the	geometric	mean	of	B2M/36b4	gene	expression.	**	677	
p	<	0.01,	***p	<	0.001,	****p	<	0.0001	by	Two	tailed	Student	T-Test.	Also	see	Figures	S2	and	S4.	678	
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	679	
Figure	3.	GDF15	expression	is	regulated	by	the	cellular	integrated	stress	response	(ISR)	pathway.		680	
(A)	GDF15	mRNA	expression	and	(C)	immunoblot	analysis	of	ISR	components	in	WT	(wild	type)	MEFs	681	
(mouse	embryonic	 fibroblasts)	 treated	with	vehicle	control	 (Con),	cobalt	chloride	 (CoCl2,	625	uM),	682	
thapsigargin	(Tg,	1	µM),	tunicamycin	(Tn	5	µg/ml)	or	L-Histidinol	(His,	1	mM)	for	6	h.	(B)	GDF15	mRNA	683	
expression	in	human	cell	lines	(HeLA,	HuH7	and	A549)	treated	with	Tn	(5	µg/ml)	for	6	h.	(D)	GDF15	684	
mRNA	expression	in	WT	MEFs	pre-treated	for	1	h	either	with	the	PERK	inhibitor	GSK2606414	(GSK,	685	
200	nM)	or	eIF2a	inhibitor	ISRIB	(ISR,	100	nM)	then	co-treated	with	Tn	(5	µg/ml)	for	a	further	6	h.	(E)	686	
GDF15	mRNA	expression	in	EIF2a	Ser51	(SS)	or	phospho-mutant	(AA)	MEFs	or	(F)	in	ATF4	wild	type	687	
(WT)	or	ATF4	knockout	 (KO)	MEFs	and	(G)	 in	control	siRNA	and	CHOP	siRNA	transfected	WT	MEFs	688	
treated	 with	 Tn	 (5	 µg/ml)	 for	 6	 h.	 (H)	 Diagram	 outlining	 pathway	 by	 which	 GDF15	 and	 FGF21	689	
expression	 is	 regulated	 by	 TN.	 mRNA	 expression	 is	 presented	 as	 fold-expression	 relative	 to	 its	690	
respective	 control	 treatment	 for	 each	 cell	 type	 (set	 at	 1)	 or	 TN	 treated	 samples	 (set	 as	 100)	with	691	
normalisation	to	HPRT	gene	expression	in	MEFs	and	GAPDH	in	human	cells.	Data	is	expressed	as	mean	692	
±	SD	from	at	least	three	independent	experiments.	***p	<	0.001	vs	control	(con)	for	A	and	B,	and	vs	693	
TN	 stimulated	 for	 D-G	 by	 Two	 tailed	 Student	 T-Test.	 Blots	 shown	 are	 representative	 of	 three	694	
independent	experiments	with	Calnexin	used	as	a	loading	control.	Also	see	Figures	S3	and	S4.	695	
	696	
Figure	4.	GDF15	is	upregulated	in	response	to	a	lysine	deficient	diet	and	induces	conditioned	taste	697	
aversion	in	mice.	698	
MS4-Mouse	study	4:	(A)	GDF15	serum	concentrations	and	(B)	ATF4	(C)	CHOP	and	(D)	GDF15	mRNA	699	
expression	in	livers	of	11-12	week-old	female	mice	that	were	fasted	overnight	and	then	fed	a	control	700	
chow	(Con)	or	lysine	deficient	diet	(-	Lys)	for	4	h.	A	blood	sample	was	withdrawn	at	1	h	following	the	701	
beginning	of	the	meal.	Serum	and	mRNA	(4	h	time-point	only)	data	is	expressed	as	mean	±	SEM	(n=6	702	
mice	per	group)	with	mRNA	normalised	to	B2M	gene	expression.,	*	p	<0.05,	**	p	<	0.01,	***p	<	0.001	703	
by	One-way	ANOVA.	704	
MS5-Mouse	study	5:	(E)	Circulating	plasma	GDF15	concentrations	after	a	single	dose	of	recombinant	705	
GDF15	in	mice;	dose	response	(n	=	3/	group).	(F	and	G)	Cumulative	food	intake	measured	between	1	706	
h	and	4	h	post	GDF15	dose	expressed	as	total	grams	(B)	or	%	of	vehicle	control	()	(n=7-8/	group).	Data	707	
is	presented	as	mean	±	SEM.	****p	<	0.0001	vs	vehicle	by	One	way	ANOVA	with	Bonferroni	multiple	708	
comparison	post	test.	 (H)	Saccharin	and	water	consumption	during	conditioned	taste	aversion	test	709	
during	GDF15	treatment	(n=8-16/	group).	Data	is	presented	as	mean	±	SEM	and	analysed	using	a	Two	710	
way	ANOVA	with	Bonferroni	multiple	comparison	post-test	to	compare	proportion	of	saccharin	water	711	
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and	water	consumption	between	groups	of	GDF15	or	LiCl	treatment	to	vehicle	****(saccharin)	or	####	712	
(water)	p	<0.0001.	Also	see	Figure	S4.	 	713	
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STAR	METHODS	714	
	715	
CONTACT	FOR	REAGENT	AND	RESOURCE	SHARING	716	
Further	information	and	requests	for	resources	and	reagents	should	be	directed	to	and	will	be	fulfilled	717	
by	the	Lead	Contact,	David	Savage	(dbs23@medschl.cam.ac.uk).	718	
	719	
EXPERIMENTAL	MODEL	AND	SUBJECT	DETAILS	720	
	721	
Human	Subjects	722	
Human	study	1:	Oral	glucose	tolerance	test	(OGTT)/Mixed	meal	723	
The	liquid	meal	test	included	12	healthy	adult	volunteers	(3	male/9	female)	with	a	mean	±	SD	age	and	724	
BMI	of	28	±	9	years	and	23.14	±	2.74	kg/m2	respectively.	Six	healthy	adult	volunteers	(4	male/2	female)	725	
were	recruited	to	participate	in	the	oral	glucose	tolerance	test	study	with	mean	±	SD	age	of	30	±	8	726	
years	and	BMI	of	25.05	 	±	 	3.73	kg/m2.	Both	studies	were	completed	at	 the	NIHR	Wellcome	Trust	727	
Clinical	 Research	 Facility	 and	 the	 Wellcome-MRC	 Translational	 Research	 Facility,	 Cambridge	728	
Biomedical	Campus,	UK.	Ethical	approval	was	obtained	 from	the	East	of	England	Cambridge	South	729	
research	ethics	committee	Ref:	16/EE/0338	and	the	East	of	England	Cambridgeshire	and	Hertfordshire	730	
research	 ethics	 committee	 Ref:	 013/EE/0195.	 Participants	 provided	 written	 consent	 prior	 to	731	
participation	in	the	study.		732	
Human	study	2:	48	hours	of	caloric	restriction	733	
14	healthy	male	volunteers	were	recruited	as	participants	in	the	study.	The	mean	±	SD	age	and	BMI	of		734	
participants	was	23.53	±	2.70	years	and	22.08	±	2.0	kg/m2	respectively.	Ethical	approval	was	obtained	735	
from	the	Cambridge	local	research	ethics	committee	(Ref:	13EE0107).	All	participants	provided	written	736	
informed	consent	before	taking	part	in	the	study	which	was	completed	at	the	NIHR	Wellcome	Trust	737	
Clinical	Research	Facility,	Cambridge	Biomedical	Campus,	UK.	738	
Human	study	3:	Low	calorie	diet	intervention	739	
50	overweight	(BMI	>27	and	<30	kg/m2)	or	obese	(BMI	30-40	kg/m2)	participants	were	enrolled	in	this	740	
study.	33	(3	male	and	30	female)	were	included	in	this	analysis	after	accounting	for	withdrawals	and	741	
insufficient	biological	samples.	Mean	±	SD	age	and	BMI	were	38.8	±	8.8	years	and	35.1	±	3.1	kg/m2	742	
respectively.		The	study	protocol	was	approved	by	the	Florida	Hospital	Institutional	Review	Board	and	743	
was	carried	out	 in	accordance	with	the	Declaration	of	Helsinki.	Clinical	trial	number:	NCT01616082	744	
(https://clinicaltrials.gov).	Before	taking	part	in	the	study,	all	participants	were	evaluated	for	eligibility.	745	
All	participants	provided	their	written	consent	to	take	part	in	the	study.	746	
Human	study	4:	Calorie	restriction	747	
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In	 total	13	healthy	adult	participants	 (7	male/6	 female)	were	 recruited	 to	 the	study.	The	 inclusion	748	
criteria	for	participation	were	age	18-45	years,	percent	body	fat	from	DEXA		>12	%	for	males	and	>15	749	
%	for	females.	Mean	±	SD	age	of	participants	was	29.7	±	6.1	years	and	BMI	was	25.04	±	3.32	kg/m2.	750	
The	study	protocol	was	initially	reviewed	by	the	Regional	Ethics	Committee	of	Norway	(2017/1052;	751	
REK	 sør-øst	 B)	with	 the	decision	 that	 the	 research	project	was	outside	 the	Act	 on	Medical	Health	752	
Research,	confirmed	in	a	letter	of	exemption	(2017/1052b).	The	study	was	then	approved	by	the	Ethics	753	
Committee	at	the	Norwegian	School	of	Sport	Sciences	(15-220817).	The	study	was	undertaken	at	the	754	
Norwegian	School	of	Sports	Sciences,	Oslo,	Norway.		Written	consent	was	obtained	from	volunteers	755	
prior	to	participation	in	the	study.	756	
Human	study	5:	7	day	high	fat	diet	overfeeding		757	
A	total	of	28	adult	participants	(25	males/3	females)	were	included	in	the	study.	Mean	±	SD	age	and	758	
BMI	 of	 the	 study	 cohort	 were	 22.6	±	 3.7	 years	 and	 24.2	±	 2.5	 kg/m2	 respectively.	 Subjects	 were	759	
physically	active	(taking	part	in	at	least	3	x	30	min	of	moderate-intensity	physical	activity	each	week),	760	
non-smokers,	with	no	diagnosis	of	cardiovascular	or	metabolic	disease,	not	 taking	any	medication,	761	
and	body	mass	was	stable	for	at	least	3	months.	Both	studies	were	approved	by	the	Loughborough	762	
University	Ethical	Subcommittee	 for	Human	Participants	 (R13-P171	and	R16-P132).	All	participants	763	
gave	written	consent	to	take	part	after	the	experimental	procedures.		764	
Human	study	6:	8	week	overfeeding	765	
20	healthy	adult	volunteers	(11	male	/9	female)	with	a	mean	±	SD	age	and	BMI	of	24.3	±	4.3	years	and	766	
25.2	±	3.0	kg/m2	 respectively	who	 led	a	sedentary	 lifestyle	 (less	 than	2	h	of	moderate	 to	vigorous	767	
exercise	per	week)	were	recruited	to	an	8	week	overfeeding	study.	Written	consent	approved	by	the	768	
Pennington	Biomedical	Research	Center	Institutional	Review	Board	was	provided	by	all	participants.	769	
This	trial	was	registered	at	clinicaltrials.gov	(number	NCT00565149).	The	study	was	undertaken	at	the	770	
Pennington	Biomedical	Research	Center	(Baton	Rouge,	Louisiana,	USA).	771	
	772	
Mouse	Studies	773	
Mouse	study	1:	Fed/Fast	study	774	
Ten	C57BL/6J	mice	were	purchased	from	Charles	River	(Charles	River	Ltd,	Manston	Rd,	Margate,	Kent,	775	
CT9	4LT)	at	7-8	weeks	of	age.		Mice	were	maintained	in	open	vented	cages	with	group	housing	(2	or	3	776	
per	cage)	in	a	12	h	light/12	h	dark	cycle	(lights	on	07:00–19:00),	temperature-controlled	(22	°C)	facility,	777	
with	ad	libitum	access	to	food	and	water.	This	research	was	regulated	under	the	Animals	(Scientific	778	
Procedures)	 Act	 1986	 Amendment	 Regulations	 2012	 following	 ethical	 review	 by	 the	 University	 of	779	
Cambridge	Animal	Welfare	and	Ethical	Review	Body	(AWERB).	780	
Mouse	study	2	and	3:	Short-	and	long-	term	high	fat	diet	studies.	781	
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C57BL/6J	mice	were	purchased	from	Charles	River	(Charles	River	Ltd,	Manston	Rd,	Margate,	Kent,	CT9	782	
4LT)	or	bred	in-house	for	some	long-term	HFD	experiments.	Mice	were	maintained	in	ventilated	cages	783	
with	 group	 housing	 (2	 or	 3	 per	 cage)	 in	 a	 12	 h	 light/12	 h	 dark	 cycle	 (lights	 on	 06:00–18:00),	784	
temperature-controlled	(20-24	°C)	facility,	with	ad	libitum	access	to	food	and	water.	All	mice	were	fed	785	
either	ad	libitum	or	as	stated	otherwise	prior	to	harvesting	tissue	and	serum	analysis.	This	research	786	
was	 regulated	 under	 the	 Animals	 (Scientific	 Procedures)	 Act	 1986	 Amendment	 Regulations	 2012	787	
following	 ethical	 review	 by	 the	 University	 of	 Cambridge	 Animal	Welfare	 and	 Ethical	 Review	 Body	788	
(AWERB).	789	
Mouse	study	4:	Lysine	nutritional	deficiency	experiment	790	
Mice	were	originally	purchased	at	Janvier	Labs	(Route	du	Genest,	53940	Le	Genest-Saint-Isle,	France)	791	
and	bred	in-house.	All	mice	were	maintained	in	standard	housing	conditions	(22	°C)	on	a	12	h	light-792	
dark	 cycle	 (lights	 on	 08:00-20:00).	 Animal	 experiments	were	 carried	 out	 in	 accordance	with	 INRA	793	
guidelines	 in	 compliance	 with	 European	 animal	 welfare	 regulation.	 Mouse	 maintenance	 and	 all	794	
experiments	have	been	approved	by	the	institutional	animal	care	and	use	committee,	in	conformance	795	
with	 French	 and	European	Union	 laws	 (permission	 to	 experiment	on	mice	 #5558,	 animal	 facilities	796	
agreement	D6334515,	GMO	agreement	#4713).	797	
For	the	lysine	nutritional	deficiency	experiment,		an	experimental	diet	was	manufactured	in	the	INRA	798	
diets	 core	 facility	 (Unité	 de	 Préparation	 des	 Aliments	 Expérimentaux,	 INRA)	 and	 nutritional	799	
experiments	were	performed	as	previously	described	(Chaveroux	et	al.,	2016;	Maurin	et	al.,	2005).	800	
Briefly,	the	nutritional	deficiency	in	an	essential	amino	acid	is	carried	out	by	means	of	experimental	801	
diets	in	which	the	protein	fraction	is	replaced	by	a	mixture	of	free	amino	acids.		802	
Mouse	study	5:	Conditioned	taste	aversion	(CTA)	test		803	
Male	C57BL/6N	mice	were	obtained	from	Taconic	Farms	Inc.	(25-30	g).	All	mice	were	maintained	in	804	
standard	housing	conditions	(21-24	°C;	45	%	humidity)	on	a	12	h	light-dark	cycle	(lights	on	06:00,	lights	805	
off	18:00).	Mice	were	singly	housed	in	the	BioDAQ	caging	system	(Research	Diets	Inc.,	New	Brunswick,	806	
NJ,	USA)	and	allowed	ad	libitum	access	to	tap	water	and	standard	rodent	chow	(Purina	5053)	unless	807	
otherwise	noted.	All	procedures	were	approved	by	 the	Pfizer-Massachusetts	Animal	Care	and	Use	808	
Committee.	809	
	810	
Eukaryotic	cell	lines		811	
Mouse	embryonic	fibroblast	(MEF)	cells	lines	were	obtained	from	David	Ron	(CIMR/IMS,	Cambridge)	812	
and	maintained	in	Dulbecco’s	Modified	Eagle’s	Medium	supplemented	with	10	%	(vol/vol)	fetal	bovine	813	
serum	 (FBS),	 2	mM	 L-glutamine,	 penicillin/streptomycin,	 1	%	 Sodium	Pyruvate,	 1	%	Non-Essential	814	
Amino	Acids	and	2-Mercaptoethanol.		HeLa	(human	cervical	carcinoma	obtained	from	ATCC),	HuH7	815	
	 23	
(human	hepatocarcinoma	obtained	from	Albert	Pol,	IDIBAPS,	Barcelona),	A549	(human	lung	epithelial	816	
carcinoma	 obtained	 from	 ATCC)	 were	 cultured	 in	 the	 same	 media	 as	 MEFs	 but	 without	 2-817	
Mercaptoethanol.	 3T3-L1	 preadipocytes	 (obtained	 from	 Zenbio)	 cells	 were	 cultured	 in	 complete	818	
DMEM	containing	10	%	newborn	calf	serum	(NCS),	2	mM	L-Glutamine,	Penicillin-Streptomycin,	1	%	819	
Non-Essential	Amino	Acids	and	1	%	Sodium	Pyruvate.	All	cells	were	maintained	at	37	°C		in	a	humidified	820	
atmosphere	of	5	%	CO2		821	
	822	
METHOD	DETAILS	823	
	824	
Human	studies	825	
Human	study	1:	Oral	glucose	tolerance	test	(OGTT)/Mixed	meal	826	
On	 the	day	before	 the	assessment	all	 participants	 received	a	 standardised	evening	meal	 at	18:00,	827	
before	commencing	an	overnight	fast.	The	energy	content	of	the	meal	was	one	third	of	a	participant’s	828	
daily	 requirements	 estimated	 from	 predicted	 resting	metabolic	 rate	 and	multiplied	 by	 an	 activity	829	
factor	of	1.35	(Schofield,	1985;	Westerterp,	1999).	Meal	composition	consisted	of	30–35	%	fat,	12–15	830	
%	protein	and	50–55	%	carbohydrate	by	energy.	Anthropometric	measurements	were	acquired	for	all	831	
participants	 on	 arrival	 to	 the	 clinical	 research	 facility.	 Participants	 were	 cannulated	 prior	 to	832	
administration	 of	 an	 oral	 liquid	meal	 consisting	 of	 a	 200	ml	 EnsureÒ	 Plus	 (Total	 energy	 330	 kcal;	833	
Protein	16.7	%,	Carbohydrate	53.8	%,	Fat	29.5	%)	or	a	glucose	drink	(50	g	anhydrous	glucose	in	200	ml	834	
water)	 with	 these	 particular	 participants	 described	 in	 Roberts	 et	 al	 (Roberts	 et	 al.,	 2018).	 Blood	835	
samples	were	taken	at	30	min	 intervals	over	the	180	min	duration	of	the	study.	EDTA	and	Lithium	836	
heparin	samples	were	placed	immediately	on	ice	while	serum	samples	remained	at	room	temperature	837	
for	30	min	prior	to	centrifugation	at	4°C	at	3500	rpm	for	10	min,	plasma	was	frozen	on	dry	ice	and	838	
stored	 at	 -70	 °C	 until	 the	 time	 of	 biochemical	 analysis.	 Assays	were	 completed	 by	 the	 Cambridge	839	
Biochemical	 Assay	 Laboratory,	 University	 of	 Cambridge.	 Serum	 GDF15	 measurements	 were	840	
undertaken	with	antibodies	&	standards	from	R&D	Systems	(R&D	Systems	Europe,	Abingdon	UK)	using	841	
a	 microtitre	 plate-based	 two-site	 electrochemiluminescence	 immunoassay	 using	 the	 MesoScale	842	
Discovery	assay	platform	(MSD,	Rockville,	Maryland,	USA).	Plasma	glucose	was	determined	using	a	843	
hexokinase	 assay	 on	 a	 Siemens	 Dimension	 ExL	 Analyser.	 Plasma	 insulin	 measurements	 using	 the	844	
Diasorin	 Liaisonâ	 XL	 automated	 	 onestep	 chemiluminesence	 immunoassay	 (Diasorin	 S.p.A,	 13040	845	
Saluggia	 (VC),	 Italy).	 Plasma	 total	 GLP-1	 was	 measured	 by	 microtitre	 plate-based	 two-site	846	
electrochemiluminescence	immunoassay	using	a	Meso	Scale	Discovery	kit	(Gaithersburg,	MD,	USA).	847	
FGF21	levels	were	measured	in	duplicate	on	serum	samples	using	the	human	FGF21	Quantikine	ELISA	848	
kit	(R&D	Systems).	849	
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Human	study	2:	48	hours	of	caloric	restriction	850	
Study	 volunteers	 attended	 the	 clinical	 research	 facility	 after	 an	 overnight	 fast.	 During	 the	 study,	851	
participants	were	required	to	eat	all	of	the	meals	provided	by	the	research	team.	For	the	first	24	h	of	852	
the	study	(day	1),	all	of	the	meals	provided	to	participants	contained	100	%	of	their	estimated	daily	853	
energy	requirements	based	on	the	Scholfield	equation	and	were	composed	of	50	%	carbohydrate,	30	854	
%	fat	and	20	%	protein	(Schofield,	1985).	Baseline	blood	tests	were	acquired	upon	waking	on	day	2	of	855	
the	study.	For	the	following	48	h	(day	2	and	3)	participants	were	calorie	restricted	to	meals	containing	856	
10	%	of	their	daily	estimated	energy	requirements.	Blood	sampling	was	repeated	upon	waking	on	day	857	
4	of	the	study	protocol,	prior	to	refeeding.	Serum	samples	remained	at	room	temperature	for	30	min	858	
prior	to	centrifugation	at	4	°C	at	3500	rpm	for	10	min,	plasma	was	frozen	on	dry	ice	and	stored	at	-80	859	
°C	until	the	time	of	biochemical	analysis.	Assays	were	completed	by	the	Cambridge	Biochemical	Assay	860	
Laboratory,	University	of	Cambridge.	Serum	GDF15	measurement	were	undertaken	with	antibodies	&	861	
standards	from	R&D	Systems	(R&D	Systems	Europe,	Abingdon	UK)	using	a	microtitre	plate-based	two-862	
site	electrochemiluminescence	 immunoassay	using	 the	MesoScale	Discovery	assay	platform	 (MSD,	863	
Rockville,	Maryland,	USA).	864	
Human	study	3:	Low	calorie	diet	intervention	865	
At	 day	 0,	 prior	 to	 initiation	 of	 the	 low-calorie	 dietary	 (LCD)	 intervention,	 baseline	 fasting	 blood	866	
sampling	and	anthropometry	were	measured.	Participants	were	provided	with	dietary	counselling	and	867	
meal-replacement	 shakes	 at	 this	 and	 subsequent	 visits,	 and	 the	 LCD	 was	 initiated.	 Participants	868	
received	a	 low-calorie	diet	for	8	weeks	at	approximately	1000	kcal	per	day,	replacing	2	meals	with	869	
approximately	600	kcal	of	meal	replacement	shakes	followed	by	a	dinner	of	approximately	400	kcal.		870	
Dinners	 were	 chosen	 from	 an	 approved	 list	 of	 Lean	 Cuisine	 and	 Healthy	 Choice	 brand	 meals.	871	
Participants	were	 free	 living	 for	 the	duration	of	 the	 study	 and	 attended	 at	 days	 14	 and	28	of	 the	872	
intervention	for	assessment	where	blood	sampling	and	anthropometric	measures	were	repeated.		873	
EDTA	plasma	samples	underwent	centrifugation	at	4	oC,	4000	rpm	for	15	min	and	stored	at	-80	oC	until	874	
analysis.	Biochemical	assays	were	undertaken	at	the	Translational	Research	Institute	for	Metabolism	875	
and	Diabetes	(Florida	Hospital).		Plasma	GDF15	was	measured	using	antibodies	&	standards	from	R&D	876	
Systems	 (R&D	 Systems	 Europe,	 Abingdon	 UK)	 using	 a	 microtitre	 plate-based	 two-site	877	
electrochemiluminescence	 immunoassay	 using	 the	 MesoScale	 Discovery	 assay	 platform	 (MSD,	878	
Rockville,	 Maryland,	 USA).	 Plasma	 leptin	 was	 assayed	 using	 the	 MesoScale	 Discovery	 platform,	879	
(Human	Leptin).	880	
Human	study	4:	Calorie	restriction	881	
Participants	were	free	living	for	the	duration	of	the	caloric	restriction.	Anthropometric	measurements	882	
were	acquired	at	baseline	and	at	the	end	of	the	study.	On	day	0	all	participants	had	a	breakfast	meal	ad	883	
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libitum	prior	to	commencing	the	caloric	restriction	to	0	kcal	per	day	for	a	total	of	7	days.	Water	was	884	
permitted	 throughout	 the	 study.	During	 the	 study,	weight	 	 (mean	±	 SD)	 fell	 from	79.6	±	5.0	 kg	at	885	
baseline	 to	73.8	±	4.8	kg	after	1	week	of	 fasting.	The	measurements	of	mean	±	SD	body	 fat	were	886	
acquired	 by	 dual-energy	 x-ray	 absorptiometry	 (DEXA)	 and	 are	 reported	 as	 an	 average	 of	 two	887	
measurements	at	baseline	on	day	-1	and	0	(18.6	±	1.8	kg)	or	following	the	fast	on	days	6	and	7	(17.3	±	888	
1.9	kg).	Participants	attended	the	research	facility	each	morning	for	phlebotomy	where	both	serum	889	
and	plasma	(EDTA	and	Lithium	Heparin)	samples	were	acquired.	Plasma	samples	were	immediately	890	
placed	on	ice	while	serum	samples	remained	at	room	temperature	for	30	min	to	coagulate	prior	to	891	
centrifugation	at	4	oC	at	3500	rpm	for	10	min.	Samples	were	then	immediately	frozen	on	dry	ice	and	892	
stored	at	-80	oC	until	the	time	of	biochemical	analysis.	Plasma	Leptin	and	GDF15	measurements	were	893	
undertaken	at	the	Cambridge	Biochemical	Assay	Laboratory,	University	of	Cambridge	using	antibodies	894	
&	standards	 from	R&D	Systems	 (R&D	Systems	Europe,	Abingdon	UK).	 	A	 two-site	microtitre	plate-895	
based	Delfia	assay	measured	Leptin.	GDF15	was	measured	using	a	microtitre	plate-based	 two-site	896	
electrochemiluminescence	 immunoassay	 using	 the	 MesoScale	 Discovery	 assay	 platform	 (MSD,	897	
Rockville,	Maryland,	USA).	The	analytic	processes	of	b-Hydroxybutyrate	were	conducted	according	to	898	
the	 manufacturer’s	 instructions.	 Plasma	 concentration	 of	 b-Hydroxybutyrate	 (mmol/l)	 were	899	
undertaken	 at	 the	 Department	 of	 Clinical	 Medicine,	 Diabetes	 and	 Hormone	 Diseases	 -	 	 Medical	900	
Research	Laboratory,	Aarhus	University,	Denmark	using	a	kinetic	enzymatic	method,	based	on	 the	901	
oxidation	of	D-3-hydroxybytyrate	to	acetoacetate	by	the	enzyme	3-Hydroxybutyrate	dehydrogenase	902	
(Randox	Laboratories	Ltd.,	Crumlin,	UK)	and	measured	on	the	Cobas	c111	system	(Roche	Diagnostics	903	
International	Ltd,	Rotkreuz,	Switzerland).	FGF21	levels	were	measured	in	duplicate	on	serum	samples	904	
using	the	human	FGF21	Quantikine	ELISA	kit	(R&D	Systems).	905	
Human	study	5:	7	day	high	fat	diet	overfeeding		906	
Prior	to	the	start	of	the	study,	subjects	attended	the	research	facility	at	Loughborough	University	for	907	
an	initial	assessment	of	their	baseline	anthropometric	characteristics.	This	information	was	then	used	908	
to	 estimate	 resting	 energy	 expenditure	 (REE)	 using	 validated	 equations	 (Mifflin	 et	 al.,	 1990).	 A	909	
standard	correction	for	physical	activity	(1.6	and	1.7	times	REE	for	females	and	males,	respectively)	910	
was	applied	in	order	to	estimate	total	daily	energy	requirements.	This	information	was	then	used	to	911	
determine	individual	energy	intakes	for	the	overfeeding	period.	Experimental	trials	were	conducted	912	
immediately	before	and	after	7	days	of	high-fat	overfeeding.	Briefly,	subjects	arrived	at	the	laboratory	913	
in	the	morning	(07:00-09:00)	after	an	overnight	fast	(≥	10	h),	having	refrained	from	strenuous	exercise	914	
for	48	h	and	having	avoiding	alcohol	or	caffeine	intake	for	24	h.	Body	mass	was	recorded	after	subjects	915	
had	voided.	A	venous	blood	sample	was	then	obtained	after	30	min	of	seated	rest.	Blood	samples	916	
were	collected	for	plasma	(EDTA)	or	serum.	Blood	samples	were	then	centrifuged,	and	the	resulting	917	
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plasma	/	serum	stored	at	-20	°C	until	analysis.	Upon	completion	of	the	first	experimental	trial,	subjects	918	
were	provided	with	all	food	to	be	consumed	for	the	following	7	days.	The	high-fat	diet	provided	19974	919	
±	474	kJ	per	day	(48	±	1	%	greater	than	estimated	daily	requirement),	with	178	±	5	g	[15	%]	protein,	920	
245	±	5	g	[21	%]	carbohydrate,	and	342	±	9	g	[64	%]	fat	intake.	Diet	compliance	was	assessed	by	daily	921	
interview.		Plasma	glucose	concentration	was	determined	using	a	spectrophotometric	assay	(Glucose	922	
PAP;	Horiba	Medical,	Northampton,	UK)	and	semi-automatic	analyser	(Pentra	400;	Horiba	Medical,	923	
Northampton,	UK).	Serum	insulin	concentration	was	determined	by	ELISA	(EIA-2935;	DRG	Instruments	924	
GmBH,	 Marburg,	 Germany).	 Serum	 Leptin	 and	 GDF15	 measurements	 were	 undertaken	 at	 the	925	
Cambridge	Biochemical	Assay	Laboratory,	University	of	Cambridge	using	antibodies	&	standards	from	926	
R&D	Systems	(R&D	Systems	Europe,	Abingdon	UK).		A	two-site	microtitre	plate-based	Delfia	assay	was	927	
used	 to	 measure	 Leptin.	 GDF15	 was	 measured	 using	 a	 microtitre	 plate-based	 two-site	928	
electrochemiluminescence	 immunoassay	 using	 the	 MesoScale	 Discovery	 assay	 platform	 (MSD,	929	
Rockville,	Maryland,	 USA).	 FGF21	 levels	 were	measured	 in	 duplicate	 on	 serum	 samples	 using	 the	930	
human	FGF21	Quantikine	ELISA	kit	(R&D	Systems).	931	
Human	study	6:	8-week	overfeeding	932	
Details	of	this	study	were	previously	described	(Bray	et	al.,	2012,	2015).	Briefly,	this	was	a	randomized,	933	
parallel-arm,	 in-patient	study.	Participants	remained	 in-patients	at	 the	Biomedical	Research	Center	934	
for	approximately	12	weeks	without	leaving.	The	first	13–25	days	of	the	in-patient	stay	(Baseline)	were	935	
used	to	establish	energy	requirements	for	weight	maintenance.	The	baseline	diet	consisted	of	361	g	936	
of	carbohydrates,	67	g	of	fat,	90	g	protein	for	a	total	of	2412	kcal.	Once	weight	stability	was	achieved,	937	
baseline	assessments	were	performed,	including	blood	draws	and	measurements	of	body	composition	938	
by	dual-energy	x-ray	absorptiometry	(DEXA).	Overfeeding	was	planned	at	approximately	40	%	above	939	
energy	requirements	for	weight	maintenance	or	approximately	1000	kcal/d	(4180	kJ/d).	During	the	940	
final	 24	 h	 period,	 the	 diet	 was	 returned	 to	 the	 baseline	 components	 and	 the	 same	 baseline	941	
assessments	were	performed	at	the	end	of	the	8	week	overfeeding.	Participants	ate	all	food	provided	942	
during	the	study	period.	Plasma	glucose	was	measured	using	a	glucose	oxidase	electrode	(DXC	600	943	
Pro;	 Beckman	 Coulter),	 and	 insulin	was	measured	 by	 an	 immunoassay	 (Immulite	 2000;	 Siemens).	944	
Plasma	 free	 fatty	 acids	 (FFAs)	 were	 measured	 with	 a	 high-sensitivity	 Wako	 kit.	 Plasma	 GDF15	945	
measurements	 were	 undertaken	 with	 antibodies	 &	 standards	 from	 R&D	 Systems	 (R&D	 Systems	946	
Europe,	 Abingdon	 UK)	 using	 a	 microtitre	 plate-based	 two-site	 electrochemiluminescence	947	
immunoassay	using	the	MesoScale	Discovery	assay	platform	(MSD,	Rockville,	Maryland,	USA).	 	948	
	949	
Mouse	studies	950	
Mouse	study	1:	Fed/Fast	study	951	
	 27	
When	aged	11-12	weeks	old,	on	day	1	of	the	study	the	mice	were	divided	into	two	groups	of	five	mice,	952	
either	“fed”	or	“fasted”.	The	body	weight	of	the	two	groups	at	study	start	were	matched	(fed	vs	fast,	953	
mean	±	SEM;	27.68	±	0.45	g	vs	27.70	±0.59	g).	At	09:00,	mice	were	transferred	into	clean	cages	in	the	954	
same	 grouped	 arrangement	 as	 during	 the	 maintenance	 period.	 Home	 cage	 bedding	 was	 also	955	
transferred	 into	clean	cages	to	reduce	stress.	Animals	 in	the	“fasted”	group	had	all	 food	removed,	956	
animals	 in	the	“fed”	had	ad	libitum	access	to	food.	All	animals	had	free	access	to	water.	24	h	later	957	
(09:00	on	day	2	of	study)	mice	were	weighed	then	received	a	terminal	dose	of	anaesthetic	(Dolethal	958	
200	mg/ml	solution,	Vetoquinol	UK	Ltd.)	given	via	the	intraperitoneal	route.	Once	unresponsive,	blood	959	
was	collected	by	cardiac	puncture,	transferred	into	a	Microtube	1.1	ml	Z-Gel	(Sarstedt	AG	&	Co)	and	960	
spun	at	10	000	x	g	for	5	min	at	room	temperature.	Serum	was	collected,	frozen	on	dry	ice	and	stored	961	
at	-80	°C	until	analysed.	After	cardiac	puncture,	body	composition	was	measured	using	DEXA	with	a	962	
Lunar	PIXImus	Mouse	Densitometer	(GE	Healthcare	Systems)	and	tissue	was	harvested,	frozen	on	dry	963	
ice	and	stored	at	-80	°C	until	being	processed.		964	
Mouse	study	2	and	3:	Short-	and	long-	term	high	fat	diet	studies.	965	
For	the	short-term	high	fat	diet	study	(Mouse	Study	2),	17-18	week	old	mice	were	fed	a	45	%	high-fat	966	
diet	(D12451i,	45	%	kcal	as	fat,	4.7	kcal/g,	Research	Diets)	for	1,	3	or	7	days.	A	separate	control	group	967	
was	kept	on	a	chow	diet	(Safe	Diets,	DS-105).		On	the	morning	(10:00)	of	the	specified	days,	mice	were	968	
weighed	and	blood	collected	by	cardiac	puncture	into	microtubes	containing	serum	gel	with	clotting	969	
activator		and	centrifuged	at	13	000	rpm	for	10	min	at	4oC	and	stored	at	-80	°C	for	serum	GDF15	and	970	
insulin	measurements.	Mouse	glucose	 levels	were	measured	 from	approximately	2	µl	blood	drops	971	
using	 a	 glucometer	 (AlphaTrak2;	 Abbot	 Laboratories)	 and	 glucose	 strips	 (AlphaTrak2	 test	 2	 strips,	972	
Abbot	Laboratories,	Zoetis).	Tissues	were	harvested	and	weighed.		973	
For	the	long-term	chronic	high	fat	diet	study	(Mouse	Study	3),	9	week-old	male	mice	were	subjected	974	
to	either	a	 chow	or	high	 fat	diet	 (as	 in	 short-term	HFD)	over	a	period	of	18	weeks.	All	mice	were	975	
weighed	 weekly	 and	 body	 composition	 was	 determined	 every	 4	 weeks	 by	 Time-Domain	 Nuclear	976	
Magnetic	Resonance	(TD-NMR)	using	a	Minispec	Live	Mice	Analyzer	(LF50,	Bruker).	Tail	blood	samples	977	
were	collected	into	heparinized	micro	blood	tubes	(01605-00,	Hawksley),	centrifuged	at	13,000	x	g	for	978	
4	min	for	plasma	GDF15,	 leptin	and	insulin	measurement.	Mouse	glucose	 levels	were	measured	as	979	
described	above	in	the	short-term	HFD	study.	At	the	end	of	the	experiment,	mice	were	fasted	for	4	h	980	
and	tissue	was	harvested	and	stored	at	-80	°C.	For	isolating	stromo-vascular	and	adipocyte	fractions,	981	
epididymal	adipose	tissue	was	minced	into	small	pieces	and	resuspended	in	5	ml	Hanks'	Balanced	Salt	982	
Solution	(Sigma)	containing	collagenase	Type	I	(Sigma).	The	tissue	was	completely	disaggregated	by	983	
incubation	in	a	37	°C	shaker	for	approximately	10	min.	The	digested	material	was	filtered	through	a	984	
100	µm	nylon	mesh	cell	strainer,	and	10	ml	of	10	%	FBS	DMEM	added.	After	a	5-10	min	incubation	at	985	
	 28	
room	temperature,	the	upper	phase	containing	the	adipocytes	was	transferred	into	a	new	tube.	The	986	
remaining	supernatant	was	centrifuged	at	700	x	g	for	10	min	and	the	pellet	containing	the	stromo-	987	
vascular	fraction	was	collected.	Both	fractions	were	frozen	at	-80	°C	until	further	analysis.	988	
Mouse	study	4:	Lysine	nutritional	deficiency	experiment	989	
Eighteen	 10	 week	 old	 C57BL/6J	 female	 mice	 were	 habituated	 to	 the	 control	 experimental	 diet	990	
(containing	20	free	amino	acids)	for	one	week.	The	night	before	the	experiment,	mice	were	fasted	for	991	
16	h	before	offering	them	a	control	meal	or	a	meal	lacking	lysine.	Mice	were	divided	into	three	groups	992	
of	six	mice:	the	first	group	was	fasted	overnight;	the	second	group	was	fasted	overnight,	then	fed	the	993	
control	diet;	the	third	group	was	fasted	overnight,	then	fed	the	lysine	devoid	diet.	A	blood	sample	was	994	
collected	from	fed	mice	at	1	h	after	the	beginning	of	the	meal	by	sub-mandibular	sampling.	At	the	995	
time	of	sacrifice	(4	h	after	the	beginning	of	the	meal	for	fed	mice),	the	blood	of	all	mice	was	withdrawn	996	
by	 cardiac	puncture	 and	 treated	with	 EDTA	 (500	mM)	along	with	 the	 tissues	being	harvested	and	997	
stored	at	-80	°C	for	analysis.	998	
Mouse	study	5:	Conditioned	taste	aversion	(CTA)	test		999	
Human	recombinant	GDF15	(Peprotech)	was	prepared	in	saline,	which	was	used	as	the	vehicle	control.	1000	
GDF15	was	administered	via	subcutaneous	 (SC)	 injection	as	a	single	dose	 in	all	mouse	studies.	LiCl	1001	
(Sigma)	was	also	prepared	 in	saline	and	administered	via	SC	 injection	as	a	single	dose	 in	all	mouse	1002	
studies.	Mice	were	acclimated	(up	to	3	days)	to	drinking	from	two	water	bottles	to	confirm	lack	of	side	1003	
preference	prior	to	habituation.	Mice	were	then	habituated	to	overnight	water	restriction	(days	1-3)	1004	
followed	by	1	h	water	bottle	presentation	 (two	bottles)	and	saline	SC	 injection.	On	day	4	 to	begin	1005	
conditioning,	mice	were	 instead	given	a	novel	0.15	%	saccharin	solution	 in	both	bottles	 instead	of	1006	
water	for	1	h,	followed	by	a	SC	injection	of	either	saline,	GDF15	(within	the	dose	range	that	induces	1007	
anorexia)	or	the	positive	control	LiCl.	Access	to	saccharin	water	was	allowed	for	an	additional	30	min	1008	
and	was	then	changed	back	to	water	until	the	next	restriction.	Day	5	was	used	as	a	GDF15	washout	1009	
period	 using	 the	 days	 1-3	 bottle	 protocol.	 A	 second	 conditioning	 period	was	 performed	 on	 day	 6	1010	
followed	by	a	washout	period	on	day	7.	On	day	8,	a	standard	two	bottle	preference	test	(saccharin	1011	
versus	water)	was	used	to	assess	CTA	development	to	the	saccharin	solution	(1	h	presentation	after	1012	
overnight	water	restriction).	The	CTA	test	was	performed	48	hours	after	the	last	GDF15	injection,	and	1013	
volume	measurements	were	for	1	hour.	Fluid	 intake	volume	was	calculated	for	both	saccharin	and	1014	
water.	The	total	volume	drunk	in	saline	group	was	1.4	ml	and	there	was	no	statistical	differences	in	1015	
the	treatment	groups.	Food	weight	was	measured	manually	using	a	digital	 scale.	Food	weight	was	1016	
measured	at	1	h	and	4	h	following	a	single	injection	of	GDF15	given	immediately	prior	to	the	onset	of	1017	
the	dark	cycle.	A	separate	group	of	mice	was	used	for	plasma	GDF15	pharmacokinetic	analysis.	Blood	1018	
was	collected	at	0.25	h,	1	h,	4	h,	8	h,	and	24	h	after	GDF15	injection	in	EDTA	tubes	containing	AEBSF	1019	
	 29	
and	aprotinin,	and	then	centrifuged	(10	000	rpm;	10	min)	for	plasma	separation	all	at	4	°C	and	then	1020	
stored	at	-80	°C.	Plasma	human	GDF15	was	measured	using	the	human	GDF15	Quantikine	ELISA	kit	1021	
per	manufacturer	instructions.			1022	
	1023	
Eukaryotic	cell	lines		1024	
Cells	were	seeded	onto	6-	or	12-well	plates	prior	to	stress	treatments	the	following	day	for	the	times	1025	
and	concentrations	indicated.	Vehicle	treatments	(e.g.	DMSO	or	ethanol)	were	used	for	control	cells	1026	
when	appropriate.		1027	
	1028	
siRNA	transfection	and	knockdown	CHOP	1029	
Wild	type	MEFs	were	seeded	onto	12-well	plates	and	transfected	with	30	nM	control	siRNA	or	siRNA	1030	
for	 mouse	 CHOP	 using	 Lipofectamine	 RNAi	 MAX	 (Invitrogen)	 according	 to	 the	 manufacturer’s	1031	
instruction.	48	h	post	siRNA	transfection,	cells	were	treated	with	ISR	stressors	for	6	h	and	subsequently	1032	
processed	for	RNA	and	protein	expression	analysis.	1033	
	1034	
RNA	isolation/cDNA	synthesis/Q-PCR	1035	
Following	treatments,	cells	were	 lysed	with	Buffer	RLT	(Qiagen)	containing	1	%	2-Mercaptoethanol	1036	
and	 processed	 through	 a	 Qiashredder	 with	 total	 RNA	 extracted	 using	 the	 RNeasy	 isolation	 kit	1037	
according	to	manufacturer’s	instructions	(Qiagen).		Meanwhile	for	mice,	tissues	were	harvested	and	1038	
immediately	snap	frozen	in	liquid	nitrogen	and	stored	at	-80	°C	until	further	analysis.	For	RNA	isolation,	1039	
approximately	30-50	mg	of	 tissue	was	placed	 in	Lysing	Matrix	D	 tubes	and	homogenized	 in	800	µl	1040	
Triazol	(Qiazol,Qiagen)	using	the	Fastprep-24	Homogenizer	for	30	sec	at	4-6	m/s	(MP	Biomedical),	or	1041	
a	rotor-stator	homogeniser.	The	resultant	supernatant	was	transferred	to	an	RNAse	free	tube	and	200	1042	
µl	chloroform	(Sigma)	added.	The	samples	were	vortexed	and	centrifuged	at	13	000	rpm	for	15	min	at	1043	
4	°C.	The	upper	phase	was	then	transferred	to	a	RNAse	free	tube	and	mixed	with	equal	volume	of	70	1044	
%	ethanol	before	loading	onto	RNA	isolation	spin	columns	(Qiagen).	RNA	was	then	extracted	(and	in	1045	
some	 instances	 treated	 with	 DNAse1	 on-column)	 using	 the	 RNeasy	 isolation	 kit	 following	 the	1046	
manufacturer´s	instructions.		1047	
RNA	concentration	and	quality	was	determined	by	Nanodrop.	400	ng	-	500	ng	of	total	RNA	was	treated	1048	
with	 DNAase1	 (Thermofisher	 Scientific)	 and	 then	 converted	 to	 cDNA	 using	 MMLV	 Reverse	1049	
Transcriptase	 with	 random	 primers	 (Promega).	 Quantitative	 RT-PCR	 was	 carried	 out	 with	 either	1050	
TaqMan™	Universal	PCR	Master	Mix	or	SYBR	Green	PCR	master	mix	on	the	QuantStudio	7	Flex	Real	1051	
time	PCR	system	(Applied	Biosystems).	All	reactions	were	carried	out	in	either	duplicate	or	triplicate	1052	
and	 Ct	 values	 were	 obtained.	 Relative	 differences	 in	 the	 gene	 expression	 were	 normalized	 to	1053	
	 30	
expression	 levels	 of	 housekeeping	 genes,	 HPRT	 or	 GAPDH	 for	 cell	 analysis	 and	 to	 B2M	 and	 36b4	1054	
geometrical	mean	for	mouse	data,	using	the	standard	curve	method.	Primer	sequences	are	shown	in	1055	
the	STAR	Methods	table.	1056	
	1057	
Serum	and	media	analysis	1058	
Tail	blood	samples	from	random	fed	or	4	h	fasted	(for	the	long	term	HFD	study)	mice	were	collected	1059	
for	 serum	analysis.	Mouse	 leptin	and	 insulin	were	measured	 simultaneously	using	a	2-plex	Mouse	1060	
Metabolic	 immunoassay	 kit	 from	 Meso	 Scale	 Discovery	 Kit	 (Rockville,	 MD,	 USA).	 The	 assay	 was	1061	
performed	 according	 to	 the	 manufacturer’s	 instructions	 and	 using	 calibrators	 provided	 by	 MSD.	1062	
Mouse	GDF15	was	measured	using	 a	Mouse	GDF15	DuoSet	 ELISA	 (R&D	Systems)	which	had	been	1063	
modified	to	run	as	an	electrochemiluminescence	assay	on	the	Meso	Scale	Discovery	assay	platform.		1064	
Mouse	FGF21	was	analysed	by	FGF21	Quantakine	ELISA	(R&D	Systems)	following	the	manufacturer’s	1065	
instructions.	Mouse	sample	measurements	were	performed	by	the	MRC	MDU	Mouse	Biochemistry	1066	
Laboratory	[MRC_MC_UU_12012/5].	For	the	human	studies,	the	details	of	the	serum/plasma	analysis	1067	
performed	are	described	separately	 for	each	study	 (see	methods	section	of	each	study	above).	All	1068	
FGF21	measurements	were	completed	by	the	Cambridge	Biochemical	Assay	Laboratory,	University	of	1069	
Cambridge	using	the	human	FGF21	Quantikine	ELISA	kit	(R&D	Systems).	1070	
	1071	
Immunoblotting	1072	
Following	treatments,	cells	were	washed	twice	with	ice	cold	D-PBS	and	proteins	harvested	using	RIPA	1073	
buffer	 supplemented	 with	 cOmplete	 protease	 and	 PhosStop	 inhibitors	 (Sigma).	 The	 lysates	 were	1074	
cleared	by	centrifugation	at	13	000	rpm	for	15	min	at	4	°C,	and	protein	concentration	determined	by	1075	
a	Bio-Rad	DC	protein	assay.	Typically,	20-30	µg	of	protein	lysates	were	denatured	in	NuPAGE	4×	LDS	1076	
sample	buffer	and	resolved	on	NuPage	4-12	%	Bis-Tris	gels	(Invitrogen)	and	the	proteins	transferred	1077	
by	iBlot	(Invitrogen)	onto	nitrocellulose	membranes.	The	membranes	were	blocked	with	5	%	nonfat	1078	
dry	milk	or	5	%	BSA	for	1	h	at	room	temperature	and	incubated	with	the	antibodies	described	in	the	1079	
STAR	methods	table.	Following	a	16	h	incubation	at	4°C,	all	membranes	were	washed	five	times	in	1080	
Tris-buffered	saline-0.1%	Tween-20	prior	to	incubation	with	horseradish	peroxidase	(HRP)-conjugated	1081	
anti-rabbit	immunoglobulin	G	(IgG),	HRP-conjugated	anti-mouse	IgG.	The	bands	were	visualized	using	1082	
Immobilon	Western	Chemiluminescent	HRP	Substrate	 (Millipore).	All	 images	were	acquired	on	the	1083	
ImageQuant	LAS	4000	(GE	Healthcare).	1084	
	1085	
QUANTIFICATION	AND	STATISTICAL	ANALYSIS	1086	
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Quantitative	data	are	reported	as	mean	±	SD	for	cells	and	mean	±	SEM	for	mouse	data.	As	indicated	1087	
in	 the	 figure	 legends,	differences	between	means	were	assessed	by	 two-tailed	Student's	 t	 tests	or	1088	
One-way	 ANOVA	 or	 Two-way	 ANOVA	 with	 Bonferroni	 multiple	 comparisons	 test	 using	 either	1089	
GraphPad	Prism	software	(GraphPad,	San	Diego)	or	with	SAS	version	9.4,	Cary,	N.	Carolina.	Statistical	1090	
significance	was	defined	as	p	<	0.05.			1091	
Data	 from	 human	 studies	 was	 analysed	 using	 GraphPad	 Prism	 software	 (GraphPad,	 San	 Diego).	1092	
Parametric	quantitative	data	is	expressed	as	mean	±	SEM	and	the	difference	in	the	mean	was	assessed	1093	
using	 a	 Two	 tailed	 student’s	 t-test.	 In	 the	 case	 of	 non-parametric	 data,	 it	 is	 reported	 as	 median	1094	
(interquartile	range)	and	compared	using	a	Wilcoxon	signed	rank,	Kruskal-Wallis	or	Mann	Whitney	1095	
test.	Details	of	specific	analyses	are	reported	in	the	respective	figure	legends.	Statistical	significance	1096	
was	defined	as	p	<0.05.			1097	
	1098	
		1099	
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Supplemental	Figure	Legends	
Figure	S1	(related	to	Figure	1).	GDF15	levels	in	response	to	a	meal	or	imposed	caloric	deficit	in	mice	and	
humans.	
HS1-Human	Study	1	(A-D):	Plasma	(A)	glucose,	(B)	insulin,	(C)	GLP-1	and	(D)	GDF15	circulating	levels	in	six	
healthy	volunteers	given	an	50	g	oral	glucose	tolerance	test	following	an	overnight	fast.	Blood	samples	
were	taken	at	serial	intervals	over	the	180	min	duration	of	the	study.	Data	is	expressed	as	mean	±	SEM.	*	
p	<0.05	comparing	to	Time	0	min	by	a	One-way	ANOVA	with	Bonferroni	post-test.	
HS2-	Human	study	2	(E)	GDF15	levels	of	14	healthy	male	volunteers	undergoing	48	h	of	caloric	restriction	
to	10	%	of	estimated	energy	requirement	per	day.	Data	is	expressed	as	mean	(SEM)	and	compared	using	
a	paired	t-test,	*	p	<0.05.	
HS5-Human	study	5	(F-J):	(F)	Body	weight,	(G)	leptin,	(H)	insulin,	(I)	glucose	and	(J)	GDF15	levels	before	
and	after	7	days	of	overfeeding	(48	±	1	%	greater	than	estimated	daily	requirements)	in	non-obese	healthy	
human	volunteers.	Data	is	from	28	adult	participants	and	expressed	as	mean	±	SEM	compared	using	a	
paired	Two	tailed	Student	t-test,	with	leptin	expressed	as	median	(IQR)	compared	using	a	Wilcoxon	signed	
rank	test,	*p	<0.05,	****	p	<0.0001.		
HS6-Human	study	6	 (K-M):	 (K)	Body	weight	 (L)	 leptin	and	 (M)	GDF15	 following	 four	or	eight	weeks	of	
overfeeding	 (additional	 40	 %	 weight	 maintenance	 energy	 requirements)	 in	 20	 volunteers.	 Data	 is	
expressed	 as	mean	 ±	 SEM.	 p	 <	 0.01,	 ****p	 <	 0.0001	 by	 a	One-way	 ANOVA	with	 Bonferroni	multiple	
comparison	post-test	**		
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Figure	S2	(related	to	Figure	2):	GDF15	is	unaffected	by	acute	HFD	(high-fat	diet)	feeding	in	mice.	
MS2-Mouse	study	2:	Plasma	(A)	GDF15,	(B)	blood	glucose	and	(C)	plasma	insulin	concentrations	from	17-
18	week-old	male	mice	that	were	either	fed	a	chow	diet	or	subjected	to	a	45%	HFD	for	1-7	days	(d).	(D)	
Liver,	(E)	epididymal	adipose	tissue	and	(F)	body	weight	from	each	diet	group.	Data	is	expressed	as	mean	
±	SEM	(n=6	mice	per	group,	except	7d,	n=5).	*	p<0.05,	***p	<	0.001	by	One	way	ANOVA	with	Bonferroni	
multiple	comparison	post	test.	
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Figure	 S3	 (related	 to	 Figure	 3).	 GDF15	 is	 regulated	 by	 the	 cellular	 integrated	 stress	 (ISR)	 response	
pathway.	(A)	GDF15	mRNA	expression	and	(B)	immunoblot	analysis	from	cell	lysates	for	ISR	components	
in	 Hela,	 HuH7	 and	 A549	 cells	 treated	with	 cobalt	 chloride	 (CoCl2,	 625	 uM),	 thapsigargin	 (Tg,	 1	µM),	
tunicamycin	(Tn	5	µg/ml)	or	L-Histidinol	(His,	1	mM)	for	6	h.		Note	for	(B),	the	arrows	denote	GDF15	protein	
and	 that	Tn	 treatment	 causes	a	mobility	 shift	 that	we	hypothesize	 is	due	 to	an	 impairment	of	GDF15	
glycosylation.	Red	asterisks	indicates	a	non-specific	band.	Whilst	GDF15	mRNA	was	induced	in	(A),	there	
was	 no	 detectable	GDF15	 protein	 in	 A549	 cells	 in	 cell	 lysates.	 (C)	 GDF15	mRNA	 expression	 in	 3T3-L1	
preadipocytes	 treated	 with	 Tn	 (5	 µg/ml)	 for	 6	 h.	 (D)	 Immunoblot	 analysis	 from	 cell	 lysates	 for	 ISR	
components	in	WT	MEFs	treated	with	TN	in	the	presence	or	absence	of	the	PERK	inhibitor	GSK2606414	
(GSK,	200	nM)	or	eIF2a	 inhibitor	 ISRIB	(ISR,	100	nM)	or	(E)	 in	Tn-treated	WT	or	ATF4	KO	MEFs.	GDF15	
mRNA	is	presented	as	fold	expression	relative	to	its	respective	control	treatment	for	each	cell	type	(set	at	
1),	normalised	to	HPRT	gene	expression	in	MEFs	and	3T3-L1	and	GAPDH	in	human	cells.	Data	is	expressed	
as	 mean	 ±	 SD	 from	 three	 independent	 experiments.	 Blots	 shown	 are	 a	 representative	 of	 three	
independent	experiments	with	Calnexin	used	as	a	loading	control.	(F)	CHOP	or	GDF15	mRNA	expression	
in	control	siRNA	and	CHOP	siRNA	transfected	WT	MEFs,	right	hand	panel,	immunoblot	analysis	from	cell	
lysates	showing	the	effectiveness	of	CHOP	siRNA	on	Tn-induced	(5	µg/ml	–	6	h)	CHOP	protein	expression.	
mRNA	data	is	mean	±	SD	from	three	independent	experiments	with	control	treated	cells	set	as	100.	***p	
<	0.001	by	Two	tailed	Student	T-Test.	Blot	shown	is	a	representative	of	three	independent	experiments	
with	Calnexin	used	as	a	loading	control.	
GDF15	upregulation	in	high-fat	fed	mice	is	associated	with	induction	of	ISR	(integrated	stress	response)	
pathways.	MS3-Mouse	Study	3:	 (A)	ATF4	 (B)	CHOP	and	 (C)	F4/80	mRNA	expression	 in	subcutaneous	 -	
(SAT),	epididymal	-	(EAT)	and	brown	(BAT)	adipose	tissue,	liver,	soleus	muscle	and	kidney	isolated	from	
C57Bl/6J	male	mice	fed	a	chow	-	(CD)	or	high-fat	diet	(HFD)	for	18	weeks	(n	=	6-8	mice/group).	mRNA	is	
presented	as	fold	expression	(mean	±	SEM)	relative	to	CD	(set	at	1)	and	normalised	to	the	geometric	mean	
of	B2M/36b4	gene	expression.	*	p	<0.05,	**	p	<	0.01,	***p	<	0.001	by	Two	tailed	Student	T-Test.	 (D)	
GDF15,	Plin1	and	F4/80	mRNA	expression	in	adipocyte	and	stromo-	vascular	fractions	(SVF)	from	18	weeks	
CD	or	HFD	epididymal	adipose	tissue.	For	GDF15,	mRNA	data	is	presented	as	fold-expression	relative	to	
chow	fed	SVF,	whereas	for	Plin1	and	F4/80,	is	presented	as	ratio	between	the	two	fractions,	with	all	data	
normalised	to	geometric	mean	of	36b4/HPRT.		Data	is	expressed	as	mean	±	SEM	and	analysed	by	Two	way	
ANOVA	with	Bonferroni	multiple	comparison	post	test	for	GDF15	and	Two	tailed	Student	T-Test	for	Plin1	
and	F4/80			*	p	<0.05,	**	p	<	0.01,	***p	<	0.001.	
	 	
HS1 - OGTT HS4
0
500
1000
1500
FG
F2
1 
(p
g/
m
l)
Chow 1d 3d 7d
HFD
*
*
MS2
FGF21 mRNA
CD HFD
0
1000
2000
3000
4000
FG
F2
1 
(p
g/
m
l)
***
MS3
0
2
4
6
8
10
SAT EAT BAT Liver Kidney Muscle
Fo
ld
 e
xp
re
ss
io
n 
(r
el
at
iv
e 
to
 M
us
cl
e 
C
D
)
Fo
ld
 e
xp
re
ss
io
n 
(R
el
at
iv
e 
to
 C
D
 S
V
F)
0
10
30
20
CD
HFD
Adipocyte SVF
**** ****
*
CD
HFD
FGF21 mRNA
A
.U
. e
xp
re
ss
io
n
0
2
1
3
4
- LysFast Con
***
***
FGF21 mRNA
FG
F2
1 
(p
g/
m
l)
**
Fed Fast
0
1000
2000
3000
5000
4000 *
FGF21 mRNA
0
0.5
1.0
1.5
2.0
A
.U
 e
xp
re
ss
io
n
Fed Fast
*
MS1
Fed Fast
A
.U
 e
xp
re
ss
io
n
0
1.0
0.5
1.5
2.0
ATF4 mRNA CHOP mRNA
Fed Fast
A
.U
 e
xp
re
ss
io
n
0
1.0
0.5
1.5
2.0
MS4
**
**
****
0
5
10
15
20
Con CoCl2 Tg Tn His
***
***
*** ***
MEFs:FGF21 mRNA
0
50
100
150
Co
n
Tn
 +
 G
SKT
n
Tn
 +
 IS
R
G
SK IS
R
***
***
R
el
at
iv
e 
ex
pr
es
si
on
 to
 T
N
  (
se
t a
s 
10
0)
Fo
ld
 e
xp
re
ss
io
n 
re
la
tiv
e 
to
 C
on
tro
l
0
5
10
15
Con Tn Con Tn Con Tn
SS
AA1
AA2
***
***
0
10
20
30
Con Tn Con Tn Con Tn
***
***
WT
ATF4KO1
ATF4KO2
Fo
ld
 e
xp
re
ss
io
n 
re
la
tiv
e 
to
 C
on
tro
l
Fo
ld
 e
xp
re
ss
io
n 
re
la
tiv
e 
to
 C
on
tro
l
R
el
at
iv
e 
ex
pr
es
si
on
 to
 T
N
  (
se
t a
s 
10
0)
0
50
100
150
200
250
Con Tn Con Tn
Control siRNA
CHOP siRNA
***
Figure S4
A B
0-1-2 1 2 3 4 5 6 7
Study day
FG
F2
1 
(p
g/
m
l)
50
0
-50
100
150
200
C
E
F G H I
J K L M
N
O P Q R
0
50
100
150
200
FG
F2
1(
pg
/m
l)
0 30 60 90 120 150 180
Time (min)
0
50
100
150
FG
F2
1(
pg
/m
l)
0 30 60 90 120 150 180
Time (min)
HS1 - Mixed meal
0
100
200
300
FG
F2
1(
pg
/m
l)
Baseline Day 7
D
HS5
	 5	
Figure	S4	(related	to	Figures	1-4).	FGF21	regulation	in	response	to	nutritional	challenges	in	mice	and	
humans.	
HS1-5	–	Human	Studies	1-5.	(A-C)	Circulatory	levels	of	FGF21	in	volunteers	that	participated	in	meal	or	
imposed	caloric	deficit	or	(D)	overfeeding	studies.	MS2-4-	Mouse	Studies	2-4.		Plasma	FGF21	and	tissue	
mRNA	expression	in	mice	subjected	to	(E)	short-term	or	(F-H)	Long-term	high	fat	or	(I)	lysine	deficient	diet.	
(J-N)	FGF21	mRNA	expression	and	its	regulation	by	the	cellular	intergrated	stress	response	pathways	in	
MEFs	.		MS1-	Mouse	study	1.	(O)	Plasma	FGF21	and	(P-R)	hepatic	FGF21,	ATF4	and	CHOP	mRNA	expression	
in	mice	subjected	to	fasting.	The	experimental	details	and	the	statistical	analysis	for	FGF21	are	identical	
to	those	conducted	for	GDF15	(see	main	and	supplemental	figures).	
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RRID:AB_627411 
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ATF4 Dr David Ron (CIMR) (Harding et al., 2000) 
Calnexin Abcam Cat# ab75801 
RRID:AB_1310022 
Anti-rabbit IgG, HRP-linked Antibody Cell Signaling Technologies Cat# 7074 
RRID:AB_2099233 
Anti-mouse IgG, HRP-linked Antibody Cell Signaling Technologies Cat# 7076 
RRID:AB_330924 
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NA 
RRID:IMSR_JAX:000664 
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Recombinant Human GDF15 Peprotech Cat# 120-28 
Lithium Chloride Sigma Cat# LX0331 
Tunicamycin Sigma Cat# T7765 
Thapsigargin Sigma Cat# T9033 
Cobalt(II) chloride hexahydrate Sigma Cat# C8661 
L-Histidinol dihydrochloride Sigma Cat# H6647 
ISRIB Sigma Cat# SML0843 
PERKi - GSK2606414 Calbiochem Cat# 516535 
TRI Reagent (Triazol) Sigma Cat# T9424 
Chloroform Honeywell Cat# C2432 
Ethanol, puriss. p.a., absolute, ≥99.8% (GC) Sigma Cat# 32221-M 
DMEM Sigma Cat# D6546 
D-PBS Sigma Cat# D8537 
Hanks' Balanced Salt Solution Sigma Cat# H9269 
L-Glutamine Sigma Cat# G7513 
Penicillin-Streptomycin Sigma Cat# P0781 
MEM Non-essential Amino Acid Sigma Cat# M7145 
	Sodium pyruvate Sigma Cat# S8636 
2-Mercaptoethanol Gibco Cat# 31350-010 
FBS Gibco Cat# 10270-106 
FetalClone™ II Serum Hyclone Cat# SH30066.03 
Sybr Green MasterMix Applied Biosystems Cat# 4309155 
Taqman MasterMix Applied Biosystems Cat# 4304437 
cOmplete™, Mini Protease Inhibitor Cocktail Sigma Cat# 11836153001 
PhosSTOP™ Sigma Cat# 4906845001 
Random primers Promega Cat# C1181 
RNasin Plus Ribonuclease inhibitor Promega Cat# N2611 
MMLV Reverse Transcriptase Promega Cat# M1701 
DNase1 Qiagen Cat# 79254 
DNase1 Thermofisher Scientific Cat# 18068015 
Lipofectamine™ RNAiMAX Invitrogen Cat# 13778-150 
Collagenase Type II from Clostridium 
histolyticum 
Sigma Cat# C6885 
NuPAGE™ 4-12% Bis-Tris Protein Gels, 1.5 
mm, 10-well 
Novex Cat# NP0335BOX 
NuPAGE™ MOPS SDS Running Buffer (20X) Novex Cat# NP0001 
NuPAGE™ LDS Sample Buffer (4X) Novex Cat# NP0007 
iBlot™ Transfer Stack, nitrocellulose, regular 
size 
Invitrogen Cat# IB301001 
Dual Color Standards BIO-RAD Cat# 1610374 
Bovine Serum Albumin Sigma Cat# A7906 
Immobilon Western (Chemiluminescent HRP 
Substrate) 
Millipore Cat# WBKLS0500 
ECL Western Blotting Detection Reagents GE Healthcare Cat# RPN2106 
Dolethal 200mg/ml Solution for injection Vetoquinol UK Ltd NA 
Biological kits   
RNAeasy Mini  Kit Qiagen Cat# 74106 
Qiashredder Qiagen Cat# 79656 
Human total GLP-1 Meso Scale Discovery Cat# K150JVC-1 
Human Active GLP-1 R&D Systems Cat#  DY957 
Human Insulin Diasorin Cat# 310360 
Human GDF15 Elisa R&D Systems Cat# DY957 
Human FGF21 Elisa R&D Systems Cat# DF2100 
Human Leptin Elisa In-house platform system 
using R&D Leptin: Cat # 
MAB398, BAM398 and 398-
LP 
https://www.cuh.nhs.uk/cor
e-biochemical-assay-
laboratory 
Mouse GDF15 Elisa R&D Systems Cat# DY6385 
Mouse FGF21 Elisa R&D Systems Cat# MF2100 
Mouse Leptin/insulin 2-Plex Meso Scale Discovery Cat# K15124C 
Experimental Models: Cell Lines   
Mouse Embryonic Fibroblasts (MEFs) Dr David Ron (CIMR) (Scheuner et al., 2001; 
Harding et al., 2003) 
HeLa ATCC Cat# CCL-2 
RRID:CVCL_0030 
	HuH7 Dr Albert Pol, IDIBAPS, 
Barcelona 
Cat# JCRB0403 
RRID:CVCL_0336 
A549 ATCC Cat# CCL-185	
RRID:CVCL_0023 
3T3-L1 Zenbio Cat# SP-L1-F 
Experimental Models: 
Organisms/Strains 
  
M. musculus: C57Bl/6J mice strain Charles River  JAX™ C57BL/6J 
RRID:IMSR_JAX:000664 
M. musculus: C57Bl/6J mice strain In House (University of 
Cambridge) 
NA  
RRID:IMSR_JAX:000664 
M. musculus: C57Bl/6N mice strain 
 
 
Taconic C57Bl/6NTac 
RRID:MGI:5658006 
 
Oligonucleotides   
Control siRNA Dharmacon Cat# D-001810-10-20 
DDIT3 siRNA smartpool On-target Plus Dharmacon Cat# L-062068-00-0005 
Human GDF15 Taqman assay Thermo Fisher Scientific Cat# Hs00171132_m1   
Human FGF21 Taqman assay Thermo Fisher Scientific Cat# Hs00173927_m1 
Mouse GDF15 Taqman assay Thermo Fisher Scientific Cat# Mm00442228_m1 
Mouse FGF21 Taqman assay Thermo Fisher Scientific Cat# Mm00840165_g1 
Human GAPDH Taqman assay Thermo Fisher Scientific Cat# Hs02758991_g1 
Human HPRT Taqman assay Thermo Fisher Scientific Cat# Hs02800695_m1 
Mouse HPRT Forward 
(AGCCTAAGATGAGCGCAAGT) 
Mouse HPRT Reverse 
(GGCCACAGGACTAGAACACC) 
This paper NA 
 
 
Mouse B2M Forward 
(ACTGATACATACGCCTGCAGAGTT)	
Mouse B2M Reverse 
(TCACATGTCTCGATCCCAGTAGA) 
This paper NA 
 
 
Mouse 36b4 Forward 
(AGATGCAGCAGATCCGCAT)	
Mouse 36b4 Reverse 
(GTTCTTGCCCATCAGCACC) 
This paper NA 
 
 
Mouse F4/80 Forward 
CAGATACAGCAATGCCAAGCA 
Mouse F4/80 Reverse 
GATTGTGAAGGTAGCATTCACAAGTG 
Mouse F4/80 Probe 
FAM-	GCAGGGCAGGGATCTTGGTTATGC-
TAMRA 
This paper NA 
Mouse CHOP Forward 
(CCACCACACCTGAAAGCAGAA)	
Mouse CHOP Reverse 
(AGGTGAAAGGCAGGGACTCA) 
This paper (Oslowski and Urano, 
2013) 
Mouse ATF4 Forward 
(GGGTTCTGTCTTCCACTCCA)	
Mouse ATF4 Reverse 
(AAGCAGCAGAGTCAGGCTTTC) 
This paper Oslowski and Urano, 2013) 
 
Software and Algorithms   
GraphPad PRISM 7 1992-2017 GraphPad 
Software, INC 
RRID:SCR_000306 
Illustrator (CS6) Adobe RRID:SCR_010279 
Photoshop (CS6) Adobe RRID:SCR_014199 
Other   
	Chow diet (mouse studies) Safe Diets Cat# R105-25 
Chow diet (mouse studies) Purina (Lab Diet) Cat# 5053 
45% High Fat Diet (mouse studies) Research Diets Cat# D12451i 
E EnsureÒ Plus  Abbot Laboratories NA 
Equipment   
ImageQuant LAS 4000 GE Healthcare Cat# 28955810 
Nanodrop 2000 Thermofisher Scientific NA 
FastPrep-24 MP Biomedical Cat# 116004500 
AlphaTrack2 Glucometer Abbot Laboratories Cat# CFMU305-H0201 
AlphaTrack2 strips Zoetis Cat# 71681-01 
Hematocrit tubes Na-Heparinized Hawksley Cat# 01605-00 
Microtube 1.1 ml Z Gel Sarstedt AG & Co Cat#  41.1378.005 
Microtube 1.1 ml Z Gel Sarstedt AG & Co Cat#  41.1500.005 
Lysing Matrix D, 2 mL Tube MP Biomedical Cat# 116913100 
Sterile Cell strainer (100 µm nylon mesh) Fisherbrand 22363549 
Minispec LF series (TD-NMR) Bruker Cat# LF50 
Lunar PIXImus Mouse Densitometer GE Healthcare Systems NA 
iBlot® Dry Blotting System Invitrogen NA 
PowerPac™ Universal Power Supply BIO-RAD Cat# 1645070 
XCell SureLock™ Mini-Cell Electrophoresis 
System 
Invitrogen Cat# EI0001 
QuantStudio 7 Flex Real-Time PCR System 
 
ThermoFisher Scientific Cat# 4485701	
 
	
 
 
 
 
 
 
 
 
 
 
